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1.	Abstract		
Bacterial	biofilms	are	an	important	and	clinically	significant	growth	state	of	bacteria.	The	
relationship	between	bacterial	antibiotic	resistance,	including	the	ability	of	a	bacterial	strain	
to	resist	multiple	drug	types,	and	biofilms	is	not	well	established.	This	research	project	
aimed	to	examine	efflux	pumps	in	Escherichia	coli	biofilms	and	how	they	influence	the	
antibiotic	sensitivity	of	a	biofilm.	This	was	done	with	the	use	of	two	efflux	pump	assays,	the	
Nile	red	real	time	assay	and	the	Hoechst	33342	assay	with	comparisons	to	biofilm	viability.	
The	efflux	pump	assays	implemented	were	modified	for	use	on	E.	coli	biofilms.	Efflux	pump	
inhibitors	(EPI)	were	used	in	conjunction	with	antibiotic	treatments	to	determine	their	effect	
on	efflux	pumps	activity	in	the	biofilm	and	cell	viability.	Well-established	EPIs	of	the	AcrAB-
TolC	pump,	CCCP	and	PAβN,	were	used	in	this	research	along	with	the	novel	inhibitor,	
capsaicin.	The	effects	of	efflux	pump	inhibitors	and	antibiotics	on	efflux	pump	transporter	
proteins	were	tested	using	single	gene	deletion	mutants.	The	data	collected	suggested	that	
the	efflux	pump	activity	of	E.	coli	biofilm	cells	behaves	differently	to	planktonic	cells;	biofilms	
appear	not	as	active	as	planktonic	cells.	In	efflux	pump	assays,	capsaicin	behaved	similarly	to	
PAβN,	a	competitive	substrate	inhibitor	and	was	less	toxic	to	the	E.	coli	biofilm,	PAβN	in	
combination	with	antibiotics	was	the	most	effective	at	E.	coli	biofilm	eradication,	however	it	
has	been	reported	to	have	toxic	side	effects.	Capsaicin	is	currently	used	pharmacologically	
and	it	therefore	is	a	potentially	clinically	significant	EPI.	Further,	the	research	suggests	that	
the	effects	of	the	sum	of	the	many	efflux	pumps	of	E.	coli	results	in	the	antibiotic	resistance	
of	the	biofilm,	minimising	the	apparent	significance	of	any	single	efflux	transporter.	
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2.	LITERATURE	REVIEW	
2.1	Biofilms:	
Biofilms	are	a	significant	contributor	to	the	occurrence	of	disease	and	infection;	reports	
suggest	biofilms	are	responsible	for	65%	of	recurrent	infections	(1).		A	biofilm	is	a	
community	of	microorganisms	that	are	submerged	in	a	self-produced	matrix	predominantly	
made	up	of	polysaccharides	as	well	as	traces	of	amino	acids,	DNA,	and	proteins	(2).	Biofilms,	
because	of	their	nature,	are	difficult	to	treat	and	to	eradicate.	Cells	in	biofilms	have	a	slower	
metabolism	in	comparison	to	their	planktonic	free-floating	counterparts	(1,	3).	They	also	
have	the	ability	to	form	persister	cells,	which	are	a	type	of	resting	state	of	the	bacterial	cell.	
In	this	state,	the	bacteria	are	tolerant	to	antibiotic	treatment;	the	cell	is	not	performing	
metabolic	activities	and	therefore	may	not	even	take	the	antibiotic	into	the	cell	(1,	4,	5).	
Biofilms	are	characterised	by	their	attachment	to	a	solid	surface.	The	extracellular	matrix	of	
the	biofilm	accounts	for	90%	of	the	biomass	and	provides	the	scaffold	for	the	3D	structure	
characteristic	of	biofilms	(6).	Biofilms	have	a	complex	structure.	The	mature	macrocolonies	
form	pillar-like	structures	that	are	surrounded	by	fluid	filled	channels	(1).	Biofilm	
development	has	five	stages	(figure	1).	The	first	is	interaction	with	a	surface,	which	is	driven	
by	Brownian	motion	and	gravitational	forces	and	is	also	influenced	by	outside	hydrodynamic	
forces	(6).	Adherence	to	the	surface	is	the	second	stage	and	is	mediated	by	the	bacterial	
cells	producing	adhesions	and	extracellular	appendages.	This	stage	of	biofilm	development	is	
reversible.	The	cells	can	detach	from	the	surface	and	revert	to	planktonic	cells.	This	
phenomenon	is	influenced	by	the	repulsion	forces	of	the	surface,	hydrodynamic	forces	and	
the	availability	of	nutrients	(6).		Providing	that	the	bacterial	cell	can	maintain	its	attachment	
to	the	surface,	irreversible	attachment	is	initiated.	It	is	at	this	third	stage	of	biofilm	
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development	that	transcriptional	changes	in	the	DNA	of	the	bacterial	cells	occur.	The	fourth	
stage	of	biofilm	development	is	maturation	in	which	the	biomass	of	the	biofilm	increases.	
The	fifth	and	final	stage	is	when	planktonic	cells	are	released	into	the	environment	from	the	
mature	biofilms	so	that	a	new	biofilm	in	a	different	location	can	be	established	(1,	6-9).	
	
Figure 1 The 5 stages of Biofilm Formation and Development, Schematic and corresponding 
electron micrographs. 1- initial attachment, 2-irreversible attachment, 3- maturation 1, 4-
maturation 2 and 5-dispsersal (10) . 	
2.1.1	Biofilm	sensitivity	to	antibiotics		
The	biofilm	and	planktonic	growth	mode	are	interchangeable	for	bacteria;	acute	infections	
are	usually	due	to	the	presence	of	planktonic	cells,	while	persistent	infections	are	commonly	
caused	by	biofilms	(11).		The	majority	of	infections	are	due	to	the	establishment	of	biofilms	
in	the	body	(1,	12).	Active	metabolism	and	cell	division	are	required	for	the	majority	of	
available	antibiotics	to	be	effective,	but	a	small	number	including	rifampicin	do	not	require	
active	metabolism	(13,	14).		Biofilms	are	typically	made	up	of	subpopulations	that	consist	of	
metabolically	active	and	inactive	cells;	the	inactive	cells	are	more	resistant	to	antibiotic	
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treatment	(15).	Biofilms	are	more	resistant	to	antimicrobials	than	planktonic	cells	(16),	there	
a	number	of	reasons	why	this	is	so.	Spoering	and	Lewis	(17)	investigation	into	Pseudomonas	
aeruginosa	revealed	that	biofilm’s	resistance	to	antibiotics	might	be	due	to	its	persistent	
stationary	phase	stage	of	growth.	They	showed	that	while	in	logarithmic	growth	biofilms	
have	much	the	same	resistance	as	logarithmic	planktonic	cultures.	They	proposed	that	it	is	
the	presence	of	the	persister	state	that	is	responsible	for	the	observable	resistance	of	
biofilms	to	antibiotics	over	planktonic	cultures	(17).		
Antibiotic	tolerance	and	antibiotic	resistance	differ	in	that	an	antibiotic-resistant	strain	has	
mechanisms	in	place	to	either	disturb	the	antibiotics	typical	method	of	action	or	by	use	of	
efflux	pumps	which	move	the	antibiotic	out	of	the	cell	before	it	accumulates	to	a	toxic	level	
(1,	4,	12).	An	antibiotic	tolerant	cell,	such	as	persister	cells,	can	tolerate	the	presence	of	
antibiotics	without	having	any	real	disruption	mechanism	in	place	(18).	Persister	cells	are	
responsible	for	reoccurrence	of	bacterial	biofilm	infections.	The	cells	reanimate	after	
antibiotic	treatments	have	eradicated	the	normal	bacterial	cells	and	can,	therefore,	establish	
a	secondary	infection	(1,	4,	12,	18,	19).	There	is	some	inconsistency	in	the	literature	about	
persister	cells.	Some	models	suggest	that	the	percentage	of	persister	cells	steadily	increases	
as	the	biofilm	reaches	maturation	and	ages	(20)	while	others	indicate	that	persister	cells	
behaviour	is	a	stationary	phase	type	model,	that	the	percentage	of	persister	cells	present	in	
a	biofilm	is	at	its	highest	level	during	the	mature	phases	of	growth	(21-23).	These	models	
may	be	contradictory,	or	they	may	model	the	actions	of	persister	cells	in	different	
circumstances	and	the	actions	of	different	species.	Defective	protein	synthesis,	protein	
aggregate	accumulation,	and	compound	signalling	are	all	factors	that	have	been	identified	as	
affecting	the	number	of	persisters	in	a	culture	(22,	24,	25).		Amato	and	Brynildsen	(26)	
identified	that	in	Escherichia	coli	the	formation	of	biofilm	persisters	is	dependent	on	ppGpp	
and	nucleoid-associated	proteins	(26).	There	has	also	been	some	microassay	indication	that	
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the	gene	ygiU	expressed	by	biofilm	forming	cells	is	also	expressed	by	persister	cells	(27).	This	
gene	is	a	global	regulator	gene	important	in	biofilm	formation	(21).	The	work	conducted	by	
Shah	et	al.	(21)	suggests	that	physiologically	and	phenotypically	persister	cells	are	distinct	
from	exponential	or	steady	growth	stages	of	the	biofilm	(21)	and	Maisonneuve	and	Gerdes	
(28)	have	suggested	as	a	mechanism	of	resistance	that	persisters	are	able	to	take	advantage	
of	their	heterogeneity	in	the	biofilm	in	order	to	evade	drug	treatments	(28).				
Whitely	et	al.	(29)	examined	P.	aeruginosa	biofilm	and	planktonic	cultures,	looking	
specifically	at	gene	expression.	A	total	of	73	genes	were	identified	as	having	differential	
expression	in	biofilm	state.	Of	these	73	genes,	34	were	activated	and	39	repressed,	evidence	
supporting	the	accepted	knowledge	paradigm	that	there	is	a	translational	change	in	the	
genes	expressed	by	biofilms.	Approximately	34%	of	the	73	genes	that	Whiteley	et	al.	(29)	
identified	have	unknown	functions.	The	authors	hypothesise	that	the	biofilm	state	offers	a	
moderate	level	of	resistance	to	antimicrobials	and	that	this	would	allow	for	the	up-
regulation	of	antibiotic	specific	genes	to	induce	a	further	level	of	resistance	(29).		Chua	et	al.	
(11)	observed	in	P.	aeruginosa	an	increased	expression	of	genes	involved	in	las	and	rhl	
quorum	sensing	in	biofilm	cells.	In	biofilms	genes	involved	in	the	matrix	were	up-regulated	
compared	to	planktonic	cells	and	genes	involved	in	motility	were	down-regulated	compared	
to	planktonic	cultures	(11).			
Quorum	sensing	in	biofilms	is	essential;	it	is	important	in	the	development	of	a	biofilm.	
Quorum	sensing	is	cell-to-cell	communication	that	synchronizes	gene	expression.	Quorum	
sensing	has	been	implicated	in	biofilm	dispersion	(30),	which	is	a	key	process	in	the	spread	of	
infection.	Quorum	sensing	and	its	role	in	the	antibacterial	sensitivity	of	biofilms	is	not	well	
understood	(31).	In	Staphylococcus	aureus	planktonic	cell	cultures,	quorum	sensing	is	
responsible	for	up-regulating	virulence	factors,	pathogenesis	and	increasing	resistance	(32).	
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Quorum	sensing	may	contribute	to	amplifying	other	mechanisms	of	resistance	that	biofilms	
already	employ	(32,	33).		Quorum	sensing	is	partially	dependent	on	efflux;	it	requires	efflux	
pumps	for	transportation	of	signalling	molecules	through	the	membrane	(34).		
Studies	that	have	examined	the	resistance	of	biofilm	and	planktonic	cells	to	antimicrobials	
such	as	polystyrene	latex	and	silver	nanoparticles	found	that	due	to	the	characteristics	of	the	
biofilm,	they	were	less	susceptible	to	the	antimicrobials	(35,	36).	The	polymeric	matrix	
protected	Pseudomonas	fluorescens	in	biofilm	from	polystyrene	latex	nanoparticles	while	
planktonic	cells	were	not	protected	and	therefore	susceptible	to	the	positively	charged	
nanoparticles	resulting	ultimately	in	planktonic	cell	death	(35).	Silver	nanoparticles	were	
found	to	be	able	to	penetrate	up	to	approximately	40µm	of	biofilm	post	1	hour	exposure,	
again	due	to	the	polymeric	matrix	aggregating	the	nanoparticles	and	preventing	diffusion	
through	the	biofilm	(36).		There	is	a	lot	of	literature	evidence	for	biofilms	being	less	
susceptible	to	antibiotics,	but	the	mechanisms	and	factors	that	contribute	to	this	
phenomenon	is	still	being	researched	and	investigated.		
2.1.2	Polymicrobial	Biofilms		
The	bacteria	that	make	up	a	biofilm	do	not	necessarily	have	to	be	of	one	strain	or	species	as	
discussed	by	Wolcott	et	al.	(19).	This	review	highlights	that	there	are	advantages	of	a	
polymicrobial	community	to	the	biofilm,	and	furthermore	that	bacteria	have	mechanisms	of	
encouraging	diversity.	Such	polymicrobial	relationships	give	a	larger	gene	pool	for	DNA	
sharing,	passive	resistance,	metabolic	cooperation	and	other	interactions	that	benefit	the	
survival	of	the	biofilm	(19).		
The	polymicrobial	biofilm	model	is	a	more	accurate	description	of	chronic	infection.	The	
original	biofilm	model,	which	is	of	single	species	biofilms,	described	by	Costerton	et	al.	(7)	
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described	acute	infections	and	lacked	the	ability	to	model	chronic	infections	(7,	19).	Newer	
biofilm	models	of	infection	have	since	been	described	that	incorporate	the	meta-genome	
and	synergies.	The	models	described	in	a	number	of	articles	have	reported	molecular	
pathways	to	reorganise	the	cellular	cytoskeleton	(37,	38),	and	breach	host	tissue	(39).	These	
in	conjunction	with	the	synergies	of	polymicrobial	biofilm	may	explain	biofilms	enhanced	
survival.		
Synergism	is	a	type	of	cooperation	in	which	the	bacterial	species	are	capable	of	independent	
growth	but	benefit	from	their	interactions	with	each	other.	This	is	a	less	specific	cellular	
communication	than	symbiosis	(40).	It	has	also	allowed	a	level	of	resistance	and	tolerance	to	
antibiotics	that	a	mono-microbial	biofilm	does	not	have.	This	is	due	to	the	protective	nature	
that	pooling	of	genetic	material	has.	This	research	has	allowed	a	better	understanding	of	the	
mechanisms	behind	biofilm	resistance	(19).		
2.2	Multi	Drug	Resistance	
Multi	drug	resistance	(MDR)	of	bacteria	is	a	significant	and	pressing	concern	to	the	human	
race;	the	WHO	has	labelled	it	of	serious	concern	(41).	The	number	of	people	who	died	as	a	
result	of	MDR	bacterial	infections	in	2014	was	an	estimated	25,000	in	Europe	and	23,000	in	
America	(42).	The	increased	prevalence	of	MDR	has	come	about	for	a	number	of	reasons.	
These	include,	over	prescription	and	overuse	of	antibiotics	and	other	antimicrobial	drugs,	a	
decline	in	discovery	and	innovations	in	new	antibiotics	and	antimicrobial	treatments	and	
therapies	(43,	44),	the	spread	of	genes	for	bacterial	mechanisms	such	as	enzyme	production	
and	overexpression	of	efflux	pumps	(41).	The	MDR	phenomenon	is	of	grave	concern	to	the	
health	of	the	community	with	resistant	strains	of	Staphylococcus	enterococcus,	and	
Pseudomonas	becoming	common	in	hospitals	(43,	45).	MDR	infection	primarily	affects	
immunocompromised	people,	such	as	individuals	undergoing	chemotherapy	for	treatment	
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of	cancer,	are	particularly	susceptible	to	MDR	infection	often	with	high	mortality	(41,	43,	
45).	It	is	also	of	concern	to	the	agriculture	and	production	industries,	which	frequently	use	
antibiotics	as	a	preventative	measure	(46,	47).	A	bacterial	population	developing	resistance	
to	antibiotics	is	somewhat	unavoidable,	even	when	used	correctly,	resistance	occurs	as	it	is	a	
natural	survival	mechanism	of	bacteria	(48),	it	is	for	this	reason	that	new	antimicrobial	
substances	and	treatments	are	required	to	be	continuously	discovered	to	maintain	the	level	
of	health	and	medical	advancement	that	we	enjoy	in	our	society.		
In	the	last	30	years,	there	has	only	been	the	discovery	of	a	single	new	class	of	antibiotics.	The	
class	of	antibiotics	known	as	teixobactin	was	discovered	by	Ling	et	al.	(49)	using	iChip	
technology.	The	chip	allows	for	the	growth	of	previously	unculturable	microorganisms	in	
nature	to	be	propagated	in	laboratory	conditions.	It	also	allows	for	any	antimicrobial	
products	that	the	microorganism	produces	to	be	isolated.	The	antibiotic	teixobactin	is	
effective	against	Gram-positive	bacteria	and	mycobacteria.	Produced	by	a	new	species	of	β-	
proteobacteria	teixobactin,	it	inhibits	peptidoglycan	biosynthesis	by	binding	a	highly	
conserved	motif	of	lipid	II	and	lipid	III.	Clinical	trials	and	further	testing	of	the	antibiotic	need	
to	occur	before	it	can	be	approved	and	marketed	as	a	new	antibiotic	suitable	for	the	
treatment	of	infections	in	humans.	However	iChip	technique	does	give	some	hope	that	new	
classes	of	antibiotics	that	will	not	encounter	immediate	resistance	mechanisms	will	be	
discovered	(49-51).			
2.3	Mechanisms	Of	Resistance		
Bacteria	have	intrinsic	mechanisms	of	resistance	that	allow	for	basic	resistance	to	antibiotics.		
Mechanisms	of	resistance	to	antibiotics	have	been	studied	extensively	in	the	planktonic	
bacterial	cell	type,	however,	in	comparison,	they	have	been	neglected	in	their	biofilm	state.	
Resistance	to	antimicrobials	predates	the	development	of	penicillin	into	clinical	use	(52).	
These	mechanisms	are	divided	into	three	main	types:	reduction	of	intracellular	
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concentrations	of	antibiotics,	modifications	to	the	antibiotic	target	via	genetic	mutation	or	
post-translational	modification	and	inactivation	of	antibiotic	via	hydrolysis	or	modification	
(42).	These	mechanisms	can	be	an	innate	ability	of	the	microorganism,	acquired	from	other	
microorganism’s	i.e.	exogenous	genetic	material,	or	as	the	result	of	mutation	(52).		The	
amplified	action	of	mechanisms	of	resistance	due	to	overexpression	or	up-regulation	of	
efflux	pumps	has	been	reported	in	multi	drug	resistant	isolates	(53-55).	
The	up-regulation	of	enzymes	such	as	β-lactamase	that	inactivate	antibiotics	before	they	can	
have	an	intracellular	effect	(42)	falls	into	the	first	type.	The	binding	sites	for	antibiotics	are	
usually	coded	for	by	multiple	genes,	but	one	alteration	to	a	single	gene	may	be	enough	to	
prevent	antibiotic	binding	or	eliminate	the	binding	site	altogether.	This	type	of	resistance	is	
an	example	of	the	second	type	(5).	Reduced	expression	of	channels	and	porins,	such	as	
OmpF	in	E.	coli	that	antibiotics	use	to	enter	cells,	and	the	overexpression	of	efflux	pumps	
that	enable	the	cells	to	remove	antibiotics	and	other	toxins	rapidly,	falls	into	the	first	group	
(5,	41).	There	is	a	research	focus	on	the	overexpression	of	multi	drug	efflux	pumps	in	
bacterial	strains.	They	have	been	identified	as	a	large	contributor	to	MDR	microorganisms	
for	some	antibiotics	(44).	
Adaptive	resistance	is	the	temporary	increase	in	the	bacteria’s	ability	to	survive	antibiotic	
exposure	due	to	alterations	in	gene	or	protein	expression	as	a	result	of	an	environmental	
trigger.	The	level	of	resistance	achieved	in	adaptive	resistance	usually	reverts	to	a	normal	
level	once	the	environmental	trigger	i.e.	the	antibiotic	is	removed.	This	phenomenon	can	be	
observed	in	multiple	generations	of	bacterial	growth	and	reversion	back	to	normal	levels	of	
resistance	can	be	observed	in	less	than	100	generations	(56,	57).	Adam	et	al.	(57)	observed	
adaptive	resistance	in	E.	coli	in	response	to	ampicillin,	tetracycline	and	nalidixic	acid	
exposure.	They	concluded	that	this	phenomenon	could	not	be	attributed	to	spontaneous	
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mutations	alone,	as	has	been	previously	theorized,	because	of	how	rapidly	the	resistance	
arises.		Suggestions	that	it	may	be	epigenetic	mechanisms	such	as	methylation	and	
stochastic	gene	expression	driving	adaptive	resistance	have	been	made	(56-59).	Increased	
expression	of	the	DAM-methylase	gene	is	associated	with	increasing	the	survival	rate	by	5x	
in	cells	treated	with	nalidixic	acid	(56,	57).	Motta	et	al.	(56)	suggested	that	the	efflux	pump	
regulatory	network	(EPRN)	is	a	target	of	epigenetic	modifications.	EPRN	is	comprised	of	two	
main	components,	an	activator,	and	a	repressor,	that	belong	to	the	same	operon.	Their	
transcription	is	auto-regulated	by	their	binding	to	the	EPRN	operon	promoter	region.	
Expression	of	the	system	when	not	exposed	to	antibiotics	is	at	low	levels	due	to	the	
repressors	higher	binding	affinity	than	the	activator	(56).	When	exposed	to	antibiotics,	the	
antibiotic	binds	to	the	repressor.	This	inactivates	it	by	preventing	the	repressor	from	binding	
to	the	transcription	site.	Allowing	the	activator	to	bind	instead,	promoting	its	expression.	
This	increases	its	concentration	and	therefore	also	increases	the	production	of	efflux	pumps	
(56).		Motta	et	al.	(56)	studied	the	EPRN	in	E.	coli	and	demonstrated	that	heterogeneity	and	
mother-daughter	correlations	affecting	transcription	rates	provided	evidence	for	the	gradual	
amplification	of	the	multi	drug	resistant	phenotype.	They	also	observed	that	introducing	a	
cost	associated	with	the	function	of	the	EPRN	was	able	to	explain	the	reversal	back	to	the	
susceptible	phenotype	(56).		
2.4	Efflux	Pumps	
Efflux	pumps	are	transporter	proteins	located	in	the	cell	membrane	of	all	organisms.	An	
active	efflux	pump	is	required	for	a	microorganism	to	be	able	to	resist	antibiotics	(43).	
However,	the	substrates	that	efflux	pumps	expel	is	not	limited	to	antibiotics.	They	are	
responsible	for	expelling	a	variety	of	substances	including	waste	and	toxins	from	the	
organism	to	prevent	cellular	damage	(41)	as	well	as	dyes,	detergents,	lipids	and	molecules	
involved	in	quorum	sensing	(43).	Drug	translocation	efflux	transporters	can	be	divided	into	
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five	families	(figure	2).	The	groups	include	major	facilitator	superfamily	(MFS)	the	resistance-	
nodulation	division	(RND),	the	ATP-binding	cassette	(ABC),	the	small	multi	drug	resistance	
(SMR),	the	multi-	drug	/	metabolite	transporter	family	(DMT),	the	multi	drug	and	toxic	
compound	extrusion	superfamily	(MATE)	(41,	43),	and	the	Proteobacterial	Antimicrobial	
Compound	Efflux	(PACE)	family(60).	Transporters	are	divided	into	these	groups	on	the	
number	of	separate	components	it	is	made	up	of,	the	trans	membrane	spanning	regions	the	
transporter	protein	has,	the	energy	source	the	protein	uses	and	the	types	of	substrate	that	
the	pump	exports	(44).	The	Major	Facilitator	family	membrane	transporters	have	between	
12	and	14	trans	membrane	domains.		
E.	coli	has	a	number	of	MFS	transporters	including	EmrB,	Bcr,	and	EmrD	(61,	62).	SMR	family	
transporters	are	small	and	commonly	only	have	4	trans	membrane	domains.	EmrE	belongs	
to	this	family.		EmrE	is	asymmetric	homodimer,	powered	by	proton	motive	force.	It	is	made	
up	of	two	subunits	that	are	antiparallel	to	each	other	(figure	4)	(63,	64).	A	tetratrimer	state	
has	also	been	reported	for	EmrE,	however	it	is	thought	the	EmrE	multrimer	variation	is	due	
to	folding	alteration	(65).	RND	transporters	are	comprised	of	a	membrane	fusion	protein	and	
an	outer	membrane	factor.	An	electrochemical	potential	gradient	established	by	hydrogen	
ion	movement	drives	the	efflux	of	the	MFS,	SMR	and	RND	families	whereas	the	ABC	family	
uses	ATP	as	its	energy	source.	The	PACE	transporters	were	recently	identified	by	Hassan	et	
al.	(60)	and	therefore	are	not	well	characterized,	it	is	proposed	that	they	are	driven	by	
hydrogen	ion	movement.	MATE	transporters	are	similar	to	MFS	in	that	they	also	have	12	
domains,	however	they	do	not	have	significant	sequence	similarity	to	the	MFS	family	(62).	
The	efflux	pump	system	responsible	for	drug	extrusion	can	be	made	of	these	transport	
families	as	well	as	other	subunits	e.g.	AcrAB-TolC	(figure	3).	Organisms	can	express	any	
number	of	different	efflux	pump	types	(44).								
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	Figure	2	Efflux	Pump	Families	and	the	substrates	specific	to	each	pump	type,	RND	family	
associates	with	outer	membrane	protein	TolC,	all	other	efflux	systems	export	into	the	
periplasm	where	they	are	exported	outside	of	the	cell	via	an	outer	membrane	protein.	(44)	
	
Figure	3	Diagrammatic	View	of	AcrAB-TolC	Efflux	Pump	System;	movement	of	hydrogen	ions,	
which	causes	a	proton	motive	force,	powers	the	pump	(66).		
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Figure	4	simplified	diagram	of	EmrE	SMR	Efflux	Pump	System	a)	opening	is	only	open	to	one	
side	of	the	membrane	during	stages	of	substrate	translocation	b)	EmrE	is	a	homodimer	made	
up	of	two	components,	the	two	subunits	exchange	confirmation	to	determine	open-in	or	
open-out	forms	(64)	
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2.4.1	Role	of	efflux	pumps	in	the	antibiotic	sensitivity	of	bacteria		
Efflux	pumps,	when	overexpressed,	can	confer	high	levels	of	resistance	to	previously	
clinically	useful	antibiotics.	All	bacteria	have	genes	for	efflux	pumps	on	their	chromosomes,	
although	some	have	been	recorded	as	being	mobilized	to	plasmids,	allowing	for	the	
overexpression	of	efflux	pumps	as	a	transmissible	mechanism	of	resistance	which	could	be	
rapidly	spread	to	other	pathogens	(42).			
Efflux	pumps	that	have	been	identified	as	being	responsible	for	MDR	include	the	resistance	
nodulation	family,	RND,	which	include	AcrAB-TolC		(figure	3)	of	E.	coli	and	MexaA-MexB-
OprM	transporter	from	P.	aeruginosa	(43,	44,	67).	RND	pumps	are	homotrimers,	and	they	
consist	of	a	pump	such	as	AcrB	that	resides	in	the	inner	membrane.	The	pump	forms	a	
tripartite	complex	with	a	periplasmic	adaptor	protein	i.e.	AcrA	or	MexA	and	an	outer	
membrane	channel	i.e.	TolC	or	OprM	(42).	Efflux	in	RND	pumps	is	driven	by	proton	motive	
force,	and	the	electrochemical	gradient	to	generate	this	is	achieved	by	the	movement	of	
hydrogen	ions	(43,	44).			
Understanding	the	mechanism	of	overexpression	is	essential	in	enabling	the	design	of	new	
therapies.	The	transcription	of	genes	that	code	for	efflux	pumps	is	controlled	by	local	
regulators,	which	are	encoded	beside	efflux	pump	genes,	and	by	global	regulators	(42).		
Overexpression	can	be	linked	to	mutations	in	the	regulatory	network	that	controls	efflux	
pump	expression.	Mutations	in	the	local	repressor,	global	transcription	factors,	and	
intergenic	sites	alter	the	expression	of	the	pump	genes	(42).	RND	pumps	such	as	AcrB	have	
been	demonstrated	by	co-crystallization	to	have	two	distinct	binding	sites	that	can	
accommodate	substrates	of	different	sizes	and	properties.		This	is	how	particular	efflux	
pumps,	such	as	AcrAB-TolC	can	export	a	range	of	antibiotics	and	substrates,	inducing	the	
antibiotic	resistance	that	is	being	seen	clinically	(42).	
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	RND	pumps	are	significant	in	Gram-negative	bacteria,	and	while	they	are	not	exclusive	to	
Gram-negative	bacteria,	they	are	more	commonly	found	in	these	organisms.	In	Gram-
positive	bacteria,	the	clinically	significant	efflux	pumps	are	members	of	the	MFS	family,	
specifically	NorA	(68,	69).	The	MFS	has	twelve	trans-membrane	helices;	four	that	face	away	
from	the	interior	and	eight	that	comprise	the	internal	cavity.	The	internal	cavity	consists	of	
hydrophobic	residues	allowing	for	the	transport	of	lipophilic	substrates.	MFS	pumps	work	via	
a	rocker-switch	alternating-access	model	(43).		
Gram-negative	bacteria	tend	to	be	more	inherently	resistant	to	antibiotics	than	Gram-
positive	bacteria	(70).	This	is	due	to	the	interactions	and	cooperation	of	multi	drug	efflux	
pumps	and	the	outer	membrane.	Gram-negative	bacteria	are	intrinsically	less	permeable	to	
antibiotics	(42).	This	does	not	however	account	for	the	increase	in	resistance	that	is	being	
observed	in	Gram-negative	bacteria	such	as	Pseudomonas	in	the	last	ten	years.	This	has	
been	attributed	somewhat	to	the	up-regulation	and	overexpression	of	efflux	pumps	(71).		
Bacterial	resistance	to	antibiotics	via	efflux	pumps	does	not	spontaneously	arise	(42).	Many	
efflux	pumps	have	large	binding	sites	that	many	antibiotics	fit	into	meaning	they	can	be	
excreted	from	the	bacterial	cell	via	that	particular	efflux	pump.	These	efflux	pumps	are	not	
designed	especially	for	antibiotics,	all	bacteria	have	a	number	of	efflux	pumps	indicating	
ancestral	origins	(72).	There	is	no	evidence	that	antibiotics	were	the	original	substrate	of	the	
efflux	pump	(52).	AcrAB	of	E.	coli	has	been	demonstrated	to	export	and	resist	bile	salts,	
which	is	consistent	with	its	role	in	protecting	E.	coli	in	the	gut	(73).		
Efflux	pumps	are	coded	for	on	both	chromosomes	and	plasmids	(74).	The	up-regulation	and	
overexpression	of	efflux	pumps	is	linked	to	the	transferable	nature	of	bacterial	genetic	
information.	Horizontal	gene	transfer	can	happen	not	only	between	microbes	of	the	same	
species	but	also	those	of	differing	species	(75,	76).	Plasmids	with	additional	copies	of	efflux	
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pumps	can	be	incorporated	into	the	genome	of	the	recipient	bacteria	resulting	in	a	higher	
number	of	efflux	pumps	in	the	membrane	of	the	bacteria	in	question.	Duplication	and	
divergence	also	leads	to	up-regulation	of	efflux	pumps,	through	transposable	elements	like	
plasmids	or	multiple	direct	or	inverted	repeat	sequences	located	in	the	chromosome	(40).	
	
2.4.2	Efflux	pumps	role	in	biofilms	
Investigations	into	efflux	pumps	in	bacterial	biofilms	have	demonstrated	that	they	have	a	
role	in	the	formation	and	development	of	the	biofilm.	Specifically	E.	coli	mutants	lacking	
efflux	transporter	genes	for	emrD,	emrE,	emrK,	acrD,	acrE	and	mdtE	were	all	reported	to	
demonstrate	an	inability	to	form	biofilm	in	comparison	to	the	E.	coli	wild	type	(3).	
Salmonella	Typhimurium	mutants	lacking	tolC	and	acrB	similarly	demonstrate	a	
compromised	ability	to	form	biofilms.	S.	Typhimurium	in	that	particular	study	that	were	
lacking	acrA	did	not	show	the	same	level	of	biofilm	forming	deficiency	(77).		TolC	in	E.	coli	
biofilms	is	essential	for	adhesion	and	biofilm	formation,	and	mutants	lacking	tolC	appear	to	
be	deficient	in	this	ability	and	have	flawed	aggregative	fimbriae	expression	due	to	a	decrease	
in	the	hydrophobicity	of	the	cell	surface	(78).	In	relation	to	antibiotic	resistance,	multi	drug	
resistant	pump	YhaQ,	which	is	unregulated	by	regulatory	protein	RapA,	was	demonstrated	
to	contribute	to	biofilm-specific	penicillin	G	resistance	in	E.	coli	(79).	Yoon	et	al.	(80)	
demonstrated	that	over	expression	of	RND	efflux	pumps	in	Acinetobacter	baumannii,	a	
clinically	significant	Gram-negative	bacteria,	contribute	not	only	to	an	increased	level	of	
resistance	observed	in	the	biofilm	but	also	adversely	affected	the	bacterium’s	ability	to	form	
a	biofilm.	The	composition	of	A.	baumannii	membranes	were	affected	and	although	this	
resulted	in	an	effect	on	biofilm	formation,	it	did	not	however	have	any	effect	on	the	
bacterium’s	motility	(80).		
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AcrAB,	pump	that	has	been	demonstrated	to	be	important	in	the	level	of	resistance	E.	coli	to	
antibiotics,	also	belongs	to	the	RND	family	(43).	This	impact	of	efflux	pump	up-regulation	
could	potentially	also	be	occurring	in	E.	coli	biofilms		
2.4.3	E.	coli	efflux	pumps		
In	E.	coli	it	is	estimated	that	approximately	20%	of	its	genome	originated	in	other	microbes	
(40).	Efflux	as	a	mechanism	of	resistance	was	first	described	in	E.	coli.	Resistance	to	
tetracycline	in	E.	coli	was	observed	and	attributed	to	a	plasmid	–	encoded	Tet	protein	(52).			
A	genome	study	of	E.	coli	identified	that	the	organism	possess	37	efflux	transporters,	both	
single	and	multi	drug	efflux	transporters,	but	not	all	of	these	transporters	are	proven.	
Transporters	include	7	ABC,	19	MFS,	1	MATE,	5	SMR	and	7	RND.	The	AcrAB-	TolC	efflux	
pump	belongs	to	the	RND	family	and	is	responsible	for	much	of	the	antibiotic	resistance	
observed	in	E.	coli	(71).		Wang	et	al,	(81)	has	recently	demonstrated	that	the	mechanism	of	
the	AcrAB-TolC	pump.	These	authors	determined	that	it	undergoes	three	distinct	
conformational	changes,	and	that	these	changes	occur	while	the	channel	is	held	open	in	a	
transport-activated	state.	They	also	demonstrated	that	this	is	linked	to	ligand	binding	which	
is	initiated	by	a	quaternary	structural	switch	(81).		
Another	efflux	pump	that	associates	with	TolC	to	form	an	efflux	pump	system	is	EmrAB,	
which	has	also	been	identified	as	playing	a	role	in	multi	drug	resistance	in	E.	coli	(82).	EmrAB	
belong	to	the	major	facilitator	family,	and	like	AcrAB	and	EmrE	it	is	dependent	on	the	
movement	of	protons	to	generate	its	functional	energy	(83).	Emr	proteins	have	been	
reported	as	conferring	resistance	specifically	to	hydrophobic	compounds	(61)		
E.	coli	also	possess	other	RND	efflux	transporters,	which	include	AcrEF,	YhiUV	and	MdtABC.	
These	transporters	require	TolC	outer	membrane	component	to	form	a	functional	efflux	
pump.	Assessment	of	these	particular	transporters	found	that	when	inactivated	they	do	not	
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affect	the	drug	susceptibility	of	E.	coli	indicating	that	they	are	not	significantly	expressed	in	
wild	type	E.	coli	(62,	71).	E.	coli	also	expresses	a	number	of	non-RND	transporters	that	
contribute	to	its	inherent	antibiotic	resistance.	These	include	EmrAB	TolC,	which	is	an	MFS	
efflux	pump	that	enables	resistance	to	nalidixic	acid.	Overexpression	of	this	pump	leads	to	
resistance	to	nalidxic	aid,	thiolactomycin,	proton	uncouplers	and	ethidium	bromide	(61,	84).	
SMR	transporter	EmrE	also	provides	intrinsic	resistance	for	E.	coli,	specifically	to	lipophilic	
substrates	such	as	ethidium	and	methyl	viogen	(85).			
E.	coli	not	only	has	multi-substrate	efflux	pumps	but	also	has	drug	specific	transporters.	
Examples	of	drug	specific	efflux	pumps	in	E.	coli	include	the	plasmid	coded	Tet	pumps,	which	
are	responsible	for	exporting	tetracycline	and	are	the	principal	resistance	mechanism	for	
tetracylines	in	Gram-negative	bacteria.	Another	drug	specific	transporter	is	MacA,	which	is	
responsible	for	exportation	of	macrolides.	To	form	a	functional	efflux	pump	MacA	requires	
TolC.	When	deleted	from	E.	coli	there	is	no	significant	impact	on	the	resistance	of	E.	coli	to	
macrolides,	however	this	is	most	likely	due	to	the	continued	function	of	the	AcrAB-	TolC	
pump	for	which	macrolides	are	also	a	substrate	of	(71).	
Given	the	transposable	nature	of	the	genetic	information	encoding	efflux	systems,	it	has	
been	suggested	that	drug	specific	efflux	originated	from	other	sources	and	are	not	
spontaneous	mutations	of	each	bacterial	species	(52).	Efflux	pump	systems	in	bacteria	are	
very	similar	amongst	the	different	resistant	species	therefore	a	treatment	developed	to	
target	a	specific	efflux	system	in	E.	coli	might	be	suitable	for	treating	the	same	efflux	system	
in	other	bacterial	species.		
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2.5	E.	coli	As	A	Model	Organism		
E.	coli	is	a	Gram-negative	organism	commonly	found	in	the	gut,	and	is	the	number	one	cause	
of	UTIs	(86).	It	is	considered	a	model	organism	for	Gram-negative	bacteria;	much	work	has	
been	performed	on	E.	coli.	It	has	had	its	entire	genome	mapped	(87)	and	was	the	first	
bacteria	in	which	efflux	as	a	mechanism	of	resistance	was	observed	(71).	
While	E.	coli	is	a	model	organism,	it	is	important	to	note	that	it	is	also	clinically	significant	in	
its	own	right.	E.	coli	is	a	normal	bacterium	in	the	healthy	gastrointestinal	micro	biome	of	
both	humans	and	animals	(88).	While	it	is	relatively	innocuous	in	the	gut	it	is	an	
opportunistic	pathogen	and	has	the	potentiality	for	it	to	become	MDR	(89).	This	would	be	a	
severe	problem	not	only	because	of	how	common	it	is	but	because	of	how	easy	it	would	be	
and	is	for	bacteria	to	colonize	other	systems	in	the	body	i.e.	urinary,	respiratory,	blood	etc.	
(88).		This	would	be	of	grave	concern	if	the	bacteria	was	untreatable	and	could	lead	to	a	
serious	public	health	problem.	A	previously	unrecognized	strain	of	E.	coli	resistant	to	
trimethoprim-sulfamethoxazole	was	identified	in	2001	by	Manges	et	al.	(90)	as	being	
responsible	for	a	11%	of	the	urinary	tract	infections	in	a	cohort	of	Californian	women.	That	
this	was	a	single	strain	of	E.	coli	affecting	a	number	of	women	suggest	that	the	strain	was	
introduced	via	ingestion.	Sahm	et	al.	(91)	identified	a	number	of	strains	isolated	from	urinary	
tracts	of	patients	in	the	United	States.	Of	these	strains	a	number	were	resistant	to	three	or	
more	antibiotics	and	therefore	can	be	considered	multi	drug	resistant	(90).	This	trend	is	of	
serious	concern	if	the	strain	continues	to	develop	further	resistance	or	as	a	indication	of	how	
simple	it	is	for	resistant	E.	coli	to	be	introduced	into	a	population	(90).		
E.	coli	wild	type	K-12	is	relatively	innocuous	however	there	are	strains	of	E.	coli	that	are	
more	cause	for	concern.	E.	coli	O157	is	one	such	strain;	infections	are	commonly	associated	
with	symptoms	ranging	in	severity	such	as	watery	diarrhea,	hemorrhagic	colitis,	hemolytic-
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uremic	syndrome	and	death.	The	variability	of	symptoms	is	thought	to	be	due	to	genetic	
heterogeneity	(92,	93).			
While	the	focus	of	this	research	is	efflux	pumps,	it	is	important	to	recognize	the	other	
mechanisms	of	multi	drug	resistance.	This	was	touched	on	briefly	in	previous	section	2.3	
Mechanisms	of	Resistance;	specifically	for	E.	coli	influx	mechanisms	also	contribute	to	MDR	
that	is	observable	in	the	organism.	The	major	outer	membrane	proteins	(OMP)	belonging	to	
E.	coli	are	OmpF	and	OmpC	these	have	a	two	part	regulatory	system	comprised	of	OmpR	and	
EnvZ	(83).	β	-	lactam	antibiotics	utilize	OMP	to	enter	E.	coli	cells,	multi	drug	resistance	is	
contributed	to	by	the	complicated	systems	that	E.	coli	has	in	place	to	recognize	toxic	
compounds	via	the	OMP	and	membrane	permeability	system	(94).		
E.	coli	is	one	of	the	most	well	studied	organisms	when	it	comes	to	its	genome.	Comprised	of	
4700	kilo	base	pairs	its	genetic	information	is	organised	into	a	singular	circular	DNA	molecule	
(87).	Whole	genome	sequencing	of	K-12	strains	MG1655	and	W3110	have	provided	the	most	
accurate	mapping	of	any	genome	(95).	The	mapping	of	the	E.	coli	also	allowed	for	the	
development	of	the	KEIO	collection,	which	is	a	collection	of	strains	of	E.	coli	characterised	by	
each	strain	being	a	single	deletion	mutant.	This	collection	has	allowed	for	a	better	
understanding	of	the	functionality	of	each	of	the	individual	non-essential	genes	of	E.	coli	and	
has	provided	researchers	with	a	great	resource	for	systems	biology	approaches	(96,	97).	E.	
coli	efflux	transporter	knockout	mutants	have	varied	antibiotic	sensitivities,	depending	upon	
the	gene	that	has	been	deleted.		Antibiotic	sensitivity	profiles	of	knockout	mutants	for	acrA,	
acrB,	tolC	show	they	are	more	sensitive	to	antibiotics	than	their	parent	strain	(98).	As	do	
other	strains	that	have	knockouts	for	efflux	transporters.	The	Knockout	mutants	in	this	
research	project	were	sourced	from	this	collection.		
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2.6	E.	coli	Biofilms		
Biofilms	are	characterized	by	a	change	in	the	gene	expression	of	the	organism	in	question	
upon	attachment.	Approximately	38%	of	the	E.	coli	genome	has	been	identified	by	gene	
fusion	studies	to	be	affected	by	biofilm	formation.	DNA	arrays	indicate	that	between	5-12%	
of	the	E.	coli	genome	is	subject	to	differential	expression	depending	on	whether	the	
bacterium	is	in	planktonic	or	biofilm	growth	stage	(99).		
Ito	et	al.	(100)	showed	that	E.	coli	biofilm	has	higher	antibiotic	resistance	and	that	the	genes	
some	efflux	pumps	were	up	regulated	in	biofilms	(100).		Matsumura	et	al.	(3)	identified	that	
multi	drug	efflux	pumps	are	important	in	the	development	of	mature	biofilms.	In	the	study	
they	developed	biofilms	using	knockouts	mutants	of	E.	coli	for	efflux	transporter	genes	
including	acrA,	acrB,	emrE,	emrB,	emrA	and	observed	that	there	was	a	reduction	in	biofilm	
formation	in	comparison	to	the	wild	type	K-12	E.	coli	(3).			
2.7	Efflux	Pump	Inhibitors	
Efflux	pump	inhibitors	(EPI)	have	the	potential	to	provide	a	means	of	inhibiting	efflux	of	
antibiotics	as	a	means	of	MDR	and	therefore	have	been	a	research	focus	for	some	time	(43,	
101).	EPIs	are	substances	that	inhibit	efflux	pump	activity	via	one	of	a	number	of	
mechanisms	i.e.	disrupting	interactions	between	the	pump	proteins,	blocking	the	exit	with	
competing	substrates	and	targeting	protein-protein	interfaces	preventing	the	formation	of	
efflux	pumps	(43,	101).	Recent	advances	towards	efflux	pump	inhibition	have	been	focused	
on	molecular	methods	and	novel	EPIs.	EPIs	have	the	potential	to	provide	a	way	of	inhibiting	
efflux	of	antibiotics	as	a	means	of	MDR	and	therefore	have	been	a	research	focus	for	some	
time	(43,	101).		Some	research	into	whether	EPIs	have	an	effect	on	the	ability	of	bacterium	
to	for	a	biofilm	has	also	been	conducted	with	promising	results	(77).	EPIs	inhibit	efflux	pump	
activity	via	one	of	a	number	of	mechanisms	including	disrupting	interactions	between	the	
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pump	proteins,	blocking	the	exit	with	competing	substrates	and	targeting	protein-protein	
interfaces	preventing	the	formation	of	efflux	pumps	(43).		
Phenylalanine-arginine	beta-naphthylamide	(PAβN)	and	Carbonyl	cyanide	m-
chlorophenylhydrazone	(CCCP)	are	well-researched	EPIs	of	the	AcrAB-	TolC	efflux	pump	
(102,	103).	PAβN	(figure	6),	a	peptidomimetic	compound,	is	commonly	used	in	research	in	
conjunction	with	fluoroquinolone	antibiotics.	PAβN	competitively	binds	to	substrate	binding	
pockets	of	RND	pumps	(104).	It	is	considered	a	broad	spectrum	EPI	due	to	it	having	been	
recorded	as	restoring	the	antibacterial	properties	a	number	of	antibiotic	families	previously	
resisted	including	chloramphenicol	and	macrolides	(105).	Using	molecular	dynamics	
simulation,	Kinana	et	al.	(106)	identified	that	PAβN	binds	to	the	binding	site	of	AcrB.	It	moves	
slightly	out	of	contact	with	the	binding	site	and	into	contact	with	a	glycine-rich	loop.	The	
loop	separates	the	distal	pocket	from	the	more	proximal	region	of	the	protein	and	is	thought	
to	control	the	access	of	substrates	to	the	distal	pocket.	By	doing	this	PAβN	blocks	the	efflux	
pump	(106).		
CCCP	(figure	5)	is	a	proton	uncoupler.	CCCP’s	mechanism	of	efflux	pump	inhibition	is	the	
uncoupling	of	oxidative	phosphorylation.	This	disrupts	the	proton	gradient	of	the	membrane	
of	a	cell,	de-energising	the	efflux	pump.	CCCP	will	be	utilised	in	this	research	project	because	
of	its	mechanism.	It	has	EPI	effects	on	a	number	of	efflux	pump	systems	including	AcrAB-
TolC	and	other	members	of	the	RND	superfamily	(107).		
Opperman	et	al.	(108)	performed	a	comprehensive	cell-based	screening	campaign	to	identify	
small	molecules	that	would	inhibit	efflux	and	work	in	conjunction	with	the	antibiotic	
ciprofloxacin,	which	is	an	antibiotic	to	which	resistance	is	frequently	reported.	They	
identified	a	novel	pyranopyridine	inhibitor	of	the	AcrAB	pump	of	E.	coli	and	suggested	that	
this	EPI	would	potentially	be	effective	as	an	adjunctive	therapy	in	conjunction	with	
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ciprofloxacin	or	a	β-	lactamase	inhibitor	(108,	109).		This	method	of	high	output	screening	of	
molecules	could	potentially	be	an	effective	method	of	discovering	a	clinically	or	industrially	
significant	novel	EPI	however	requires	an	abundance	of	both	time	and	resources.	
Other	molecules	and	compounds	that	have	been	established	to	have	an	inhibitory	effect	on	
efflux	activity	of	one	or	more	bacterial	species	in	recent	studies	include	Kalia	et	al.’s	
investigation	(110)	into	the	flavonoid	capsaicin	(figure	7),	the	molecule	that	gives	chilli	its	
intense	heat.	This	study,	which	established	that	capsaicin	is	an	EPI	of	NorA	efflux	pump	of	S.	
aureus,	was	performed	on	a	single	species	and	this	particular	species	was	tested	on	a	
planktonic	growth	state	only	(110).	
	
	
Figure	5	Carbonyl	cyanide	m-chlorophenylhydrazone	(CCCP)	Molecular	Structure	(111)	
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Figure	6	Phenylalanine-arginine	beta-naphthylamide	(PAΒN)	Molecular	Structure	(111)	
	
 
Figure	7	The	Molecular	Structure	of	Capsaicin	(111)	
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2.8	Methodologies	And	Fluorescent	Dyes	Used	To	Study	Efflux	Pumps	
	
The	advancements	in	methodologies	that	have	occurred	in	recent	years	are	leading	to	a	
better	understanding	of	the	molecular	mechanism	of	action	(MOA)	of	EPIs.	Such	
methodologies	include	computational	modelling	methods.	RND	pumps,	in	particular,	are	
modelled	using	computational	programs	to	investigate	protein	interactions	in	efflux	pumps	
and	how	the	EPI	interacts	with	the	pump.	Trott	et	al.	(112)	reported	using	a	program	called	
AutoDock	Vina	which	is	a	docking	algorithm	binding	sites	and	in	the	absence	of	a	binding	site	
to	identify	energetically	favourable	sites	of	small	molecules.	A	more	advanced	software	
being	used	is	the	complex	MD	simulations	that	Durrant	et	al.	(113)	published	work	on	and	
also	reviewed	these	systems	simulations	for	proteins	(113).	Other	biochemical	methods	for	
the	investigation	into	MOA	include	binding	assays	such	as	isothermal	titration	calorimetry	as	
described	by	Nakashima	et	al.	(114),	and	fluoresce	polarization	of	substrate	compounds	
(114).	Biochemical	assays	include	cell-	based	efflux	pump	activity	assay;	e.g.,	nitrocefin	assay	
which	was	developed	by	Nagano	et	al.	(115)	and	can	be	used	to	assess	effects	of	EPI	on	
AcrAB-TolC	(101,	115).		
Many	of	the	assays	used	to	measure	the	activity	of	efflux	pumps	use	easy	to	observe	
fluorescent	compounds.	The	uptake	and	subsequent	residence	or	removal	of	these	
compounds	can,	therefore,	be	used	to	monitor	the	activity	of	efflux	mechanisms.	Non-
biochemical	assays	designed	to	measure	efflux	activity	traditionally	utilize	stains	such	as	
Acridine	orange,	Berberine	and	Ethidium	Bromide	(EtBr).	Coldham	et	al.	(116)	have	
described	an	assay,	which	utilizes	the	fluorescent	dye	Hoechst	33342.	They	found	that	the	
Hoechst	33342	assay	was	a	more	sensitive	and	specific	assay	for	MDR	Salmonella	mutants	
than	EtBr	(116).	In	addition	to	being	inexpensive	and	relatively	rapid,	Hoechst	33342	is	a	
safer	alternative	to	the	traditionally	used	EtBr.	EtBr	binds	to	DNA	in	an	intercalation	form	
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between	base	pairs	(117)	EtBr	is	not	used	as	frequently	in	microbiology,	and	molecular	
biology	labs	as	the	dye	has	been	found	to	be	highly	toxic,	it	causes	cellular	neurotoxicity	
when	tested	on	rats	4	(118)	and	has	mutagenicity,	carcinogenicity	and	teratogenicity	
potentials	(119).	Hoechst	33342	is	readily	taken	up	by	living	cells	and	is	nontoxic;	it	has	been	
shown	to	not	adversely	affect	living	cells	after	exposure	to	the	Hoechst	dye.	Cell	viability	is	
maintained	at	a	concentration	10μM	it	also	found	that	there	is	not	significant	damage	to	the	
DNA	of	the	living	cells	exposed	with	Hoechst	33342	(120,	121).		The	dye	binds	to	the	minor	
groove	of	the	DNA	helix	and	has	an	affinity	for	AT-rich	regions	of	four	or	more	base	pairs	
(122).			
Nile	red	is	a	lipophilic	dye	used	in	a	similar	fashion.	The	assay	developed	by	Bohnert	et	al.	
(123)	initially	was	designed	as	a	systematically	optimized	real	time	dye	efflux	assay	for	the	
measurement	of	AcrAB-TolC	efflux	pump	activity	in	E.	coli,	one	that	would	also	allow	for	the	
detection	of	competition	between	substrates.	The	Nile	red	assay	utilizes	the	addition	of	the	
EPI	CCCP	to	prevent	Nile	red	from	being	expelled	preemptively	from	the	cells.	Once	
monitored	for	a	number	of	cycles	using	fluorescence	the	cells	are	energized	with	the	
addition	of	glucose.	The	lipophilic	dye	is	then	pumped	rapidly	out	of	preloaded	bacterial	
cells,	giving	a	real-time	reflection	of	efflux	pump	activity.		A	limitation	of	other	efflux	pump	
activity	assays	including	EtBr	and	Hoechst	33342	accumulation	assays	(123)	is	that	the	real	
time	measurement	cannot	be	taken.	There	is	some	delay	in	which	a	certain	amount	of	dye	
can	accumulate	in	the	cells	before	fluorescence,	this	differs	to	the	level	of	background	
fluorescence	a	cell	puts	out	on	its	own	when	untreated	with	a	dye	(122).		
These	assays	and	methodologies,	while	effective,	have	some	of	the	following	limitations;	
they	do	not	give	a	real	time	indication	of	efflux	activity,	lack	the	ability	to	indicate	cell	
membrane	permeability,	or	indicate	what	efflux	family	is	expelling	the	drug.		Biochemical	
assays	in	comparison	to	efflux	pump	assessment	methodologies	described	above	do	not	
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require	highly	specialized	equipment	or	specific	training	and	therefore	are	used	more	
frequently.	However,	they	are	limited	by	their	lack	of	ability	to	show	the	mechanisms	of	
action	of	the	efflux	pumps	being	tested.	Computational	methodologies	have	the	advantage	
in	this	regard.		
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3.	Aims	and	objectives		
	
Both	efflux	pumps	and	biofilms	are	associated	with	MDR	and	recurrent	infections,	but	
currently,	the	significance	of	efflux	pump	activity	to	MDR	in	biofilms	is	not	well	understood.	
The	overexpression	of	efflux	pumps	and	antibiotic	sensitivity	has	been	studied	in	a	
planktonic	cell	types	and	has	been	neglected	in	biofilms.	This	research	aims	to	ultimately	
identify	the	effect	of	efflux	pumps	on	antibiotic	sensitivity	of	E.	coli	biofilms.		Using	efflux	
pump	assays,	examining	the	efflux	response	of	E.	coli	and	E.	coli	efflux	pump	deletion	strains	
exposed	to	antibiotic	and	EPI	treatments,	will	attempt	to	do	this.	The	objectives	of	this	
research	project	are	to:	
• Adapt	existing	efflux	pump	assays	(Hoechst	33342	efflux	pump	assay	and	Nile	red	
real	time	efflux	pump	assay)	so	they	are	suitable	for	use	on	E.	coli	biofilms.		
• Test	the	effect	of	efflux	pump	inhibitors	on	biofilms	of	E.	coli	wild	type	and	single	
deletion	mutants	with	inactivated	efflux	pump	components	using	efflux	pump	assays.			
• Evaluate	the	effect	on	the	efflux	pump	activity	and	viability	of	biofilms	of	E.	coli	and	
deletion	E.	coli	mutants	with	inactivated	efflux	pump	components,	in	the	presence	of	
antibiotics	and	efflux	pump	inhibitors.	
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4.	MATERIALS	AND	METHODS	
4.1	Media	and	Reagents	
Luria	Bertani	(LB)	broth	(Miller)	and	Agar	Technical	(Agar	No.	3)	were	purchased	from	Oxoid,	
Australia.	LB	agar	was	prepared	from	LB	broth	and	1.2%(w/v)	agar	to	manufacturers	
directions	and	sterilized	for	15min	at	121	°C.	Dilution	blanks	were	prepared	at	0.1%	(w/v)	
concentrations	using	bacteriological	peptone	(Oxoid)	and	sterilized	for	15min	at	121	°c.		
Phosphate	buffered	saline	(PBS)	was	made	up	by	adding	8g	NaCl,	0.2	g	KCl,	1.44g	Na2HPO4,	
0.2	g	KH2PO4	to	800	mL	distilled	water	add.	The	pH	was	adjusted	to	7.4	with	HCL	before	
bringing	the	total	volume	to	1	L	with	distilled	water.	PBS	was	then	sterilized	by	autoclaving	at	
121	°C	for	15min.		
4.2	Bacterial	Strains		
Bacterial	strains	were	purchased	from	the	KEIO	collection	at	the	Coli	Genetic	Stock	Centre	
(Yale	University,	New	Haven,	CT).	These	microorganisms	were	received	on	small	discs	of	
paper	and	were	reconstituted	with	LB	broth	as	per	supplier’s	instructions.	Single	deletion	
knockout	mutants	of	E.	coli	were	used	in	this	project	(Table	1).		Wild	type	K12	E.	coli	was	
sourced	from	the	Western	Sydney	University	Culture	Collection	on	a	nutrient	agar	slope;	this	
organism	was	originally	purchased	from	Coli	Genetic	Stock	Centre	(Yale	University,	New	
Haven,	CT),	November	2011.		Wild	type	K12	E.	coli	is	the	parent	strain	from	which	the	single	
deletion	knockout	mutants	are	derived.		
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TABLE	1	KEIO	COLLECTION	KNOCKOUT	MUTANTS	USED	IN	RESEARCH	PROJECT	
Strain	 Chromosomal	marker	 Deletion	 Gene	function	
JW0451-2	 ∆acrB747::kan	 acrB	 RND	efflux	transporter	
component	of	the	AcrAB-	
TolC	Tripartite	efflux	pump	
(62,	109)	
Jw0452-3	 ∆acrA748::kan	 acrA	 MFP	efflux	transporter	
component	of	the	AcrAB-	
TolC	Tripartite	efflux	pump	
(62,	108)	
Jw0531-2	 ∆emrE750::kan	 emrE	 A	proton	linked	multi	drug	
transporter	belonging	to	the	
SMR	family	(62,	124)	
Jw2260-1	 ∆emrA766::kan	 emrA	 A	periplasmic	membrane	
fusion	protein.	Component	of	
the	tripartite	Efflux	pump	
EmrA-EmrB-TolC	(62,	114,	
125)	
Jw2661-1	 ∆emrB767::kan	 emrB	 Inner	membrane	transporter.	
Component	of	the	tripartite	
Efflux	pump	EmrA-EmrB-TolC	
(62,	125)	
Jw3368-1	 ∆ompR739::kan	 ompR		 Transcriptional	regulatory	
protein.	Regulates	the	
transcription	of	major	OMP	
OmpM	and	OmpF,	suggested	
to	regulate	other	OMP	(62)	
Jw5503-1	 ∆tolC732::kan		 tolC		 Outer	membrane	protein,	
Outer	membrane	transporter	
for	a	number	of	efflux	
systems	(62)	reports	of	OmpR	
positively	regulating	AcrAB-
TolC	(126)	
4.3	Maintenance	of	Bacterial	Cultures	
Freeze	dried	samples	of	the	knockout	strains	were	prepared	and	added	to	the	Western	
Sydney	University	culture	collection.	The	cultures	were	maintained	on	LB	slopes	for	the	
duration	of	the	study.	Slopes	were	prepared	by	aseptically	transferring	a	loop	full	of	culture	
and	incubating	at	37°C	for	24	hours.	After	incubation	the	slopes	were	refrigerated	at	4°C	
between	uses.		Fresh	slopes	were	prepared	every	4	weeks.		Overnight	culture	of	E.	coli	wild	
type	and	deletion	mutants	were	prepared	for	biofilm	development	by	inoculating	10mL	of	LB	
broth	from	slopes	and	incubating	16	hours	at	37	°C.			
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4.4	Antibiotics		
Antibiotics	used	in	this	research	project	were	purchased	from	Sigma	Aldrich,	Castle	Hill,	
Australia.	Antibiotics	were	chosen	because	of	literature	reports	of	them	being	expelled	by	E.	
coli	AcrAB-TolC	pump	system	and	they	cover	a	range	of	mechanisms	of	action	(127).	
Antibiotics	were	diluted	from	stock	concentrations	to	achieve	MIC	as	obtained	from	
Andrews	(128).	Antibiotics	were	made	up	to	concentrations	as	per	table	3.	
TABLE	2	ANTIBIOTIC	TREATMENTS	FOR	BIOFILMS	INCLUDING	MIC	AND	DILUENTS,	MIC	OBTAINED	FROM	
ANDREWS	(128)	
Antibiotic	 Solvent	 Stock	
concentration	
(mg/	10	mL)	
Working	MIC	for	
biofilms		
μg/mL	(128)	
Ampicillin	 Ethanol	 16	 16	
Rifampicin	 DMSO		 64	 64	
Chloramphenicol		 Ethanol	 128	 128	
Nalidixic	acid		 Ethanol		 128	 128	
3.5	Efflux	Pump	Inhibitors	
Inhibitors	were	purchased	from	Sigma	Aldrich,	Castle	Hill,	Australia.	They	were	diluted	from	
stock	concentrations	as	per	table	4.	Working	concentrations	were	used	for	all	treatments	
unless	otherwise	specified.		
TABLE	3	EFFLUX	PUMP	INHIBITORS	
Inhibitor	 Solvent	 Stock	
concentration	
(mM/10mL)	
Working	Concentration	
	(μM)	
Capsaicin	 Ethanol	100%	 2	 10	
PAβN	 Ethanol	100%	 2	 10	
CCCP	 DMSO	100%	 2	 10	
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4.6	Biofilm	preparation.		
Two	different	methods	of	biofilm	preparation	were	used	in	this	research	project.		
	
4.6.1	Biofilm	developed	in	96	well	plate			
An	overnight	culture	of	E.	coli	was	incubated	for	16	hours	at	37	°C,	then	0.2mL	aliquots	of	
broth	were	dispensed	into	each	well	of	two	96	well	black	plates.	This	was	incubated	for	a	
period	of	either	48	hours	(Plate	1)	or	72	hours	(Plate	2).	After	the	72	hour	period	spent	
media	was	removed	from	the	wells	of	Plate	2,	being	careful	not	to	disrupt	the	biofilm,	and	
was	replaced	with	0.2mL	aliquots	of	fresh	LB	broth	and	incubated	for	a	further	24	hours.	
Plate	1	was	incubated	for	a	period	of	48	hours	and	did	not	have	spent	media	replaced.	Both	
Plate	1	and	plate	2	were	washed	with	0.2mL	of	PBS	per	well	then	replaced	with	0.17mL	of	
PBS.	
4.6.2	CDC	Biofilm	reactor	
CDC	biofilm	reactor	(Biosurface	Technologies	Corporation,	Montana	USA)	was	assembled	by	
loading	the	rods	with	either	silicone,	or	stainless	steel	coupons	(Figure	7).	350mL	of	LB	broth	
was	then	added	to	the	vessel	and	it	was	autoclaved	at	121°C	for	15	minutes.	After	the	vessel	
and	media	had	cooled	to	room	temperature,	3.5mL	of	overnight	E.	coli	culture	was	
aseptically	added.	The	biofilm	reactor	was	then	placed	in	an	incubator	on	a	magnetic	stir	
plate	set	at	130-140rpm.	The	reactor	was	incubated	under	static	conditions	at	37°C	for	72	
hours	for	all	assays	and	24	hours	for	viability	enumeration.		
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Figure	8	CDC	Biofilm	Reactor	From	Biosurface	Technologies	Corporation,	Montana	USA	(74)	
	
4.7	Hoechst	33342	Efflux	Pump	Assay.		
The	method	used	in	this	research	project	was	modified	from	Coldham	et	al.	(116).	Which	
was	performed	on	broth	cultures	of	Salmonella	enterica	serovar	Typhimurium	and	E.	coli.	
Adjustments	were	made	to	this	method	to	improve	its	suitability	for	use	on	biofilms.	Initially	
E.	coli	biofilms	were	developed	in	a	96	well	plate	and	compared	to	the	fluorescent	readings	
obtained	for	E.	coli	using	Coldham	et	al.	(116)	method.		
Overnight	E.	coli	broth	cultures	incubated	at	37	°C	for	a	minimum	of	16	hours	were	used	to	
inoculate	fresh	LB	broth	which	was	then	incubated	for	a	further	5	hours.		Bacterial	cells	were	
collected	by	centrifugation	at	4000g	and	re-suspended	in	PBS	(1mL	PBS/	10mL	of	original	
broth).	Aliquots	of	0.17mL	were	transferred	to	wells	of	a	96	well	black	plate	(Corning	3916;	
Sigma	Aldrich,	Castle	Hill,	Australia).	A	concentration	of	25μM	of	Hoechst	33342	was	added	
to	each	treatment	well	at	a	volume	of	0.02mL.	The	fluorescence	was	then	measured	with	
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emission	and	excitation	filters	of	355	and	460nm	following	procedure	as	described	by	
Coldham	et	al.	(116).	For	analysis	of	biofilms,	biofilms	were	developed	in	a	96	well	black	
plate	(Corning	3916;	Sigma	Aldrich,	Castle	Hill,	Australia).	Fluorescence	was	measured	under	
identical	conditions	to	planktonic	variation.		
Difficulties	with	background	fluorescence	of	media	despite	washings	as	well	as	an	
inconsistent	and	varied	amount	of	growth	between	individual	wells,	resulted	in	a	high	
standard	deviation/error.		CDC	biofilm	reactors	were	used	to	develop	more	consistent	
biofilms.		
The	biofilms	were	grown	with	pure	cultures	of	wild	type	E.	coli	and	E.	coli	knockout	mutants	
(Table	1)	for	key	efflux	pump	and	outer	membrane	proteins.		Silicone	coupons	with	
developed	biofilm	were	removed	from	rods	aseptically	and	washed	with	PBS.	They	were	
then	placed	in	10mL	PBS	in	15	mL	falcon	tubes	and	sonicated	using	Sonicor	water	bath	
(Sonicor	Instrument	Corporation,	Copiague	New	York)	for	5	min	to	dislodge	biofilm	from	
coupons.	The	biofilm	PBS	solution	was	then	treated	with	EPIs	at	a	concentration	of	10mM.	
After	treatment	195μl	of	sample	was	transferred	into	a	96	well	black-bottomed	plate.	5μl	
Hoechst	33342	dye	was	added	to	a	final	concentration	of	25μM	to	each	well.	The	plate	was	
then	incubated	at	room	temperature	for	10	min.	Fluorescence	was	measured	at	excitation	
and	emission	wavelengths	of	320	and	460	with	a	BMG	labtech	CLARIOstar	for	a	period	of	30	
cycles	(cycle	time	69	sec,	total	time:	44	min	51	sec)	
4.8	Nile	Red	Assay	
Nile	red	efflux	assay	as	described	by	Bohnert	(123),	is	designed	to	assess	the	efflux	pump	
activity	and	competition	of	substrates	of	AcrAB-TolC	multi	drug	efflux	of	planktonic	cells.	
This	method	was	adapted	in	the	course	of	this	research	to	be	performed	on	biofilm	cells.		
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Biofilms	were	set	up	as	previously	described	for	Hoechst	33342	assay.		CDC	biofilm	reactors	
were	incubated	for	a	period	of	72	hours	at	36°c.	Stainless	steel	coupons	were	aseptically	
removed	from	containers	and	washed	with	PBS.	Washing	of	coupons	was	repeated	an	
additional	time.	Coupons	placed	in	a	24	well	plate	with	2mL	aliquots	of	PBS.	CCCP	(5mM	
stock	solution	in	50%	DMSO)	added	to	each	well	to	give	a	final	concentration	of	5μM.	Cells	
were	allowed	to	rest	for	15	min.	For	competitive	substrate	analysis	antibiotics	as	potential	
competitors	were	added	to	a	final	MIC	as	per	table	3.	MIC’s	were	taken	from	Andrews	(128)	
upper	limit	of	MIC.		Potential	competitor	treatments	included	both	inhibitors	and	antibiotics	
singly	and	in	combinations	of	both.	Biofilms	were	allowed	to	rest	for	15	min	post	competitor	
treatment.	Nile	red	(5mM	in	90%	ethanol)	was	added	to	each	well	to	a	final	concentration	of	
5μM.	The	24	well	plate	containing	coupons	and	treatments	were	incubated	on	a	shaker	(140	
rpm	37	°c)	for	3	hours.	Cells	were	removed	from	the	incubator	and	allowed	to	rest	at	room	
temperature	for	60	min.	Coupons	were	removed	from	wells	and	placed	in	15mL	falcon	tubes	
in	2mL	aliquots	of	PBS	in	presence	of	competitor.	Falcon	tubes	were	sonicated	in	water	bath	
for	5min	to	dislodge	biofilms	from	their	respective	coupons.	200μl	of	each	sample	was	
immediately	transferred	to	96	well	black-bottomed	plates	and	fluorescence	was	read	using	
BMGlabtech	CLARIOstar,	with	excitation	wavelength	552	nm	and	emission	wavelength	636	
nm.	Fluorescence	was	read	for	a	period	of	10	cycles	(cycle	time	79	seconds,	total	time:	11	
min	51	s),	Nile	red	efflux	was	then	triggered	by	rapid	energisation	with	10μl	of	1M	glucose	
(pause	time	approximately	4	min	+/-	45	sec)	and	monitored	for	a	further	30	cycles	(total	
time:	39	min	30	sec).	
4.9	Enumeration	of	Viable	Cells		
After	incubation	coupons	with	24-hour	biofilm	were	removed	from	rods	aseptically	and	
washed	with	PBS	as	outlined	in	4.6.2.	They	were	then	placed	in	24	well	microtiter	plate	with	
2mL	PBS	with	antibiotics	and	EPI	treatments	as	per	concentrations	in	Table	2	and	Table	3.	
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They	were	incubated	for	6	hours	at	37	°C.	Coupons	were	then	transferred	to	10mL	PBS	in	15	
mL	falcon	tubes	and	sonicated	for	5	min	to	dislodge	biofilm	from	coupons.	Treatments	
performed	on	each	coupon	were	a	combination	of	an	inhibitor	and	an	antibiotic.	Control	
groups	were	an	untreated	group	only	in	the	presence	of	PBS,	and	groups	singularly	treated	
with	an	antibiotics	or	inhibitor.		
Once	sonicated	serial	dilutions	(10-1-10-3)	were	performed	by	transferring	1mL	of	sample	to	a	
9mL	bacteriological	peptone	blanks.	1mL	from	each	dilution	blank	was	transferred	to	a	petri	
dish	and	pour	plates	were	prepared	using	LB	agar.	After	incubation	for	24	hours	at	37	°C,	
plate	counts	were	conducted	in	order	to	calculate	the	number	of	viable	cells	in	colony	
forming	units	per	millilitre	(cfu/mL)	of	PBS.	Cfu	was	calculated	per	mL	of	PBS	diluent,	actual	
cfu	per	coupon	is	10	times	cfu/mL.	Limit	of	detection	for	all	treatments	was	calculated	to	be	
1.5	Log10	cfu/coupon.		
4.10	Statistical	Analysis	
Statistical	analysis	was	performed	on	data	from	Hoechst	33342	efflux	pump	assay,	Nile	red	
real	time	efflux	pump	assay	and	enumeration	of	viable	cells	using	Microsoft	Excel.	Standard	
error	was	calculated	for	all	treatments	and	assay	results	where	the	number	of	replicates	was	
greater	than	two.		
	
	
	
	
	
Gemma	Deakin	17117500		
46	|	P a g e 	
5.	RESULTS	
5.1	Detecting	efflux	activity	in	biofilms		
There	are	a	number	of	assays	that	measure	efflux	pump	activity	in	a	bacterial	culture,	
however	these	are	commonly	performed	on	planktonic	cultures.	An	important	requirement	
of	this	research	project	was	to	adapt	existing	efflux	pump	activity	assays	for	use	with	
biofilms.	Two	assays,	the	Nile	red	real	time	efflux	pump	assay	and	the	Hoechst	33342	efflux	
pump	assay	were	chosen	to	adapt	and	determine	whether	they	could	be	used	to	detect	the	
efflux	pump	activity	of	biofilms.	
5.1.1	Adapting	the	Nile	red	real	time	efflux	pump	assay	for	detection	of	biofilm	
efflux	pump	activity	
The	Nile	red	real	time	efflux	pump	assay	described	by	Bohnert	et	al.	(123)	was	modified	from	
use	with	planktonic	cultures	for	use	on	biofilm	cells	in	this	research	project.	The	biofilms	
used	were	grown	on	stainless	steel	coupons	in	the	CDC	biofilm	reactor	as	Nile	red	is	highly	
lipophilic	and	was	absorbed	by	the	silicone	coupons	rather	than	taken	up	by	the	biofilm	
during	initial	trials	of	the	assay.	The	assay	was	performed	on	E.	coli	wild	type	biofilm	and	
planktonic	cultures,	and	sonicated	to	remove	the	biofilms	from	the	coupons.	The	
modification	to	the	method	was	also	trialled	on	a	selected	deletion	mutant,	tolC	JW5503	to	
observe	how	fluorophore	accumulation	in	biofilms	compared	to	planktonic	cultures	and	if	
the	efflux	of	biofilms	could	be	detected	with	this	method.	The	planktonic	method	followed	
was	as	described	by	Bohnert	et	al.	(123).	The	results	as	shown	in	figures	9	and	10,	indicate	
that	the	response	of	biofilm	and	planktonic	cultures	were	very	different.	When	glucose	was	
added	to	the	sample,	efflux	was	initiated	in	the	wild	type	planktonic	culture.	This	is	
represented	by	the	sharp	decrease	in	fluorescence	observable	at	10	min	in	figure	9.	The	
planktonic	culture	of	tolC	deletion	mutant	(figure	9)	and	biofilm	cultures	of	wild	type	and	
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tolC	deletion	mutant	(figure	10)	did	not	behave	the	same	way	as	the	wild	type	planktonic	
culture	in	reaction	to	the	addition	of	glucose.	The	level	of	fluorescence	instead	started	to	
increase	indicating	that	Nile	red	was	accumulating	in	the	bacterial	cells	in	response	to	the	
addition	of	glucose.	This	method	was	continued	with	biofilm	cultures	of	all	deletion	mutants	
because	it	showed	that	it	was	capable	of	demonstrating	changes	in	efflux	pumps	in	biofilms	
when	treated	with	EPIs.	
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Figure	9	Nile	red	real	time	efflux	pump	assay	performed	on	planktonic	culture	of	E.	coli	K12	
wild	type	and	tolC	deletion	(JW5503).	24hr	old	culture	grown	on	shaker	exposed	to	
fluorophore	for	4	hours	prior	to	measurement.	Fluorescence	measured	for	10	cycles	before	
addition	of	glucose.	
Figure	10	Nile	red	real	time	efflux	pump	assay	performed	on	biofilm	culture	of	E.	coli	K12	
wild	type	and	tolC	deletion	(JW5503).	72hr	old	biofilm	grown	on	stainless	steel	coupons	
exposed	to	fluorophore	for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	
measured	for	10	cycles	before	addition	of	glucose.			
0	
2000	
4000	
6000	
8000	
10000	
12000	
0	 500	 1000	 1500	 2000	 2500	
Fl
uo
re
sc
en
ce
	(F
l)	
Time(	seconds)	
E.coli	K12	
Wildtype	
Planktonic		
tolC	
deleron	
Planktonic		
Glucose	added		
0	
500	
1000	
1500	
2000	
2500	
3000	
0	 500	 1000	 1500	 2000	 2500	
Fl
uo
re
sc
en
ce
	(F
l)	
Time	(seconds)	
E.coli	
K12	
Biofilm	
tolC	
deleron	
Biofilm	
Glucose	added	
Gemma	Deakin	17117500		
49	|	P a g e 	
5.1.2	Adapting	Hoechst	33342	efflux	pump	assay	for	detection	of	biofilm	efflux	
pump	activity.	
Hoechst	33342	efflux	pump	assay	was	initially	developed	for	use	on	planktonic	cultures.	This	
assay,	as	described	by	Coldham	et	al.(116),	was	adapted	during	the	course	of	the	current	
research	project	for	biofilms	grown	on	silicone	coupons.	Comparisons	between	the	Hoechst	
33342	efflux	pump	assay	performed	on	biofilm	and	planktonic	cultures	(figure	11),	
demonstrates	that	while	the	biofilms	yielded	a	lower	fluorescence	than	the	planktonic	
cultures,	the	trends	in	regards	to	the	EPI	treatments	of	biofilm	culture	are	reflected	in	the	
trends	of	the	planktonic	culture.	It	is	also	observable	in	this	graph	that	the	standard	error	
calculated	for	each	sample	is	a	much	tighter	range	for	biofilms	in	comparison	to	planktonic	
culture.	The	fluorescence	readings	and	differences	in	samples	indicate	that	the	method	was	
measuring	Hoechst	33342	efflux	in	biofilms.	Based	on	these	findings	the	same	method	was	
carried	out	on	E.	coli	efflux	transporter	deletion	mutants.		
Figure	11	Hoechst	33342	endpoint	assay	performed	on	E.	coli	wild	type	overnight	planktonic	
cultures	and	48hr	biofilm	cultures.	Both	biofilm	and	planktonic	cultures	were	treated	with	
EPIs	CCCP,	PAβN	and	Capsaicin		
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5.2	How	do	efflux	pump	inhibitors	influence	with	biofilm	efflux?			
Efflux	pump	inhibitors	were	used	to	determine	their	effect	on	both	wild	type	and	deletion	
mutants,	using	both	Nile	red	real	time	efflux	pump	assay	and	Hoechst	33342	efflux	pump	
assay.		EPIs	were	used	at	a	concentration	of	10μM,	unless	otherwise	specified.	Plate	counts	
were	also	performed	to	determine	toxicity	effect	on	E.	coli	wild	type	and	deletion	mutants.		
5.2.1	Efflux	pump	activity	in	the	presence	and	absence	of	EPIs	using	Nile	red	real	time	
efflux	pump	assay		
Nile	red	real	time	efflux	pump	assay	was	used	to	examine	biofilms	response	to	the	EPIs	used	
in	this	project.	Biofilm	coupons	were	treated	with	CCCP	to	prevent	efflux	of	the	Nile	red	and	
treatments.	The	samples	were	then	exposed	to	EPIs	as	well	as	Nile	red	dye	at	37	°C	for	3	
hours.	After	an	hour	of	resting	at	room	temperature	the	samples	were	removed	and	
dispensed	into	a	96	well	black	plate.	Fluorescence	was	measured	for	a	period	of	10	cycles	
(approximately	600	seconds)	before	glucose	was	added.	Fluorescence	was	subsequently	
measured	for	another	30	cycles	post	glucose	addition.	The	Y-axis	on	the	Nile	red	assay	
graphs	for	E.	coli	deletion	mutants	was	set	to	1800	Fl;	however	it	was	set	to	6000	Fl	for	E.	
coli	K12	wild	type	due	to	the	higher	level	of	fluorescence	produced.	Thus	for	the	control	
treatment	the	wild	type	ranged	from	2000	to	2500	post	glucose	treatments	whereas	all	
mutants	had	a	range	for	controls	below	1500.		
During	the	4hrs	incubation	exposure	to	Nile	red,	the	wild	type	control	accumulated	the	most	
Nile	red,	and	it	had	the	highest	fluorescence	at	time	0	min.		In	comparison,	mutants	had	all	
accumulated	less	the	50%	the	amount	that	the	control	had	by	time	0	min.	Deletion	mutants	
emrE	and	emrA	accumulated	the	most	Nile	red	initially	at	time	0	min.		During	the	assay	wild	
type	accumulated	the	most	Nile	red;	the	difference	between	initial	and	final	readings	is	
greater	in	wild	type	biofilms	than	deletion	mutants.	Of	the	deletion	mutants	ompR,	emrA	
and	emrB	accumulated	the	most	Nile	red.	Capsaicin	is	a	less	effective	inhibitor	than	PAβN	in	
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these	treatments.	The	values	obtained	for	mutants	and	wild	type	are	less	than	the	controls	
but	the	shape	of	graphs	are	similar.		
For	the	ompR	and	acrB	mutants	Nile	red	accumulation	had	similarities	to	that	observed	in	
the	wild	type.	While	there	was	lower	fluorescence	and	each	treatment	was	closer	in	
fluorescence	to	each	other	the,	the	order	of	Nile	red	accumulation	reflects	the	order	
displayed	by	the	wild	type.		TolC	deletion	and	acrA	deletion	had	similar	levels,	increased	at	a	
similar	rate	after	the	addition	of	glucose	and	accumulated	the	same	orders	of	Nile	red	with	
EPI	treatments.	EmrE,	emrB	and	emrA	mutants	had	very	similar	patterns	of	Nile	red	
accumulation	with	Nile	red	accumulation	highest	in	the	untreated	control.	Levels	of	
accumulation	for	emrA	and	emrE	across	all	EPI	treatments	were	very	similar.		
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Figure	12	Nile	red	real	time	efflux	pump	assay	performed	on	E.	coli	wk12	wild	type	biofilm.	72hr	old	
biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)		
Figure	13	Nile	red	real	time	efflux	pump	assay	performed	on	tolC	deletion	(JW5503)	biofilm.	72hr	old	
biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)			
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Figure	14	Nile	red	real	time	efflux	pump	assay	performed	on	acrB	deletion	(JW0451)	biofilm.	72hr	old	
biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)		
	
	
Figure	15	Nile	red	real	time	efflux	pump	assay	performed	on	acrA	deletion	(JW0452)	biofilm.	72hr	old	
biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)	
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Figure	16	Nile	red	real	time	efflux	pump	assay	performed	on	emrA	deletion	(JW2660)	biofilm.	72hr	
old	biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)			
Figure	17	Nile	red	real	time	efflux	pump	assay	performed	on	emrB	deletion	(JW2661)	biofilm.	72hr	
old	biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)		
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Figure	18	Nile	red	real	time	efflux	pump	assay	performed	on	emrE	deletion	(JW5031)	biofilm.	72hr	
old	biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)		
Figure	19	Nile	red	real	time	efflux	pump	assay	performed	on	ompR	deletion	(JW3368)	biofilm.	72hr	
old	biofilm	grown	on	stainless	steel	coupons	exposed	to	fluorophore	and	efflux	pump	inhibitors	for	4	
hours	prior	to	suspension	and	measurement.	Fluorescence	measured	for	10	cycles	before	addition	of	
glucose.	Error	bars	represent	standard	error	(n=	6)			
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5.2.2	Efflux	pump	activity	in	the	presence	and	absence	of	EPIs	using	Hoechst	
33342	efflux	pump	assay		
Hoechst	33342	efflux	pump	assay	was	performed	on	72	hour	biofilms	treated	with	EPIs	and	
Hoechst	33342	fluorescent	dye.	This	assay	was	performed	to	examine	the	response	of	the	
deletion	mutants’	biofilm	efflux	pump	activity,	as	represented	by	the	accumulation	of	
Hoechst	33342,	to	EPIs.	The	cells	were	incubated	for	10	min	prior	to	their	fluorescence	being	
read.	The	dye	binds	to	the	DNA	of	the	bacterial	cell	and	is	transported	out	of	the	cell	via	
efflux	pumps	(122).	An	increased	fluorescence	indicates	impaired	function	in	the	efflux	
pumps	ability	to	transport	the	dye.		
The	E.	coli	wild	type	results	(figure	20)	show	a	pattern	of	fluorescence	in	the	EPI	treatments	
that	is	similarly	reflected	in	results	obtained	for	acrA	(figure	23),	ompR	(figure	27),	emrE	
(figure	26),	and	emrA	(figure	24)	deletion	mutants.		Low	levels	of	fluorescence	were	
obtained	for	all	treatments	including	the	control	for	mutants	with	acrB	deletion	(figure	22),	
emrE	deletion	(figure	26),	and	tolC	deletion	(figure	21)	in	comparison	to	the	wild	type	(figure	
22).		AcrB,	emrE	and	tolC	deletions	all	had	similar	fluorescence	profiles,	acrB	and	tolC	both	
had	the	same	pattern	i.e.	control	had	the	lowest	fluorescence.		
The	rate	at	which	Hoechst	33342	accumulated	inside	the	cell,	indicated	by	the	increased	
slope	of	treatment	data	plots	was	highest	for	PAβN	treatment	in	acrA	deletion	(figure	23).	
Similarly	observable	in	figure	25,	emrB	deletion	mutant	also	exhibited	a	higher	rate	of	
accumulation	for	all	treatments	including	control	in	comparison	to	the	wild	type.	The	
fluorescent	profile	of	emrB	deletion	was	similar	to	the	wild	type,	which	also	showed	an	
increase	in	accumulation	of	Hoechst	33342	as	time	progressed.	Deletion	mutants	acrB	
(figure	25),	ompR	deletion	(figure	27),	emrE	deletion	(figure	26),	emrA	deletion	(figure	24),	
and	tolC	deletion	(figure	21)	had	a	steady	level	of	Hoechst	33342	present	in	the	sample,	
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while	ompR	deletion	had	a	slight	decline	in	fluorescence	and	then	plateaus	at	approximately	
15	min.
The	acrA	mutant	treated	with	capsaicin	and	PAβN	had	higher	flourecense	levels	and	
therefore	higher	accumulation	then	the	Capsaicin	and	PAβN	treatment	of	wild	type	biofilm.	
The	control	and	CCCP	treatments	gave	flourescent	profiles	that	were	very	similar	to	the	
wildtype	for	acrA	deletion	(Figure	22).
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Figure	20	Hoechst	33342	assay	performed	on	E.	coli	K12	72	hour	wild	type	biofilm	grown	on	silicone	
coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	bars	
represent	standard	error	(n=	6)	
	
Figure	21	Hoechst	33342	assay	performed	on	tolC	deletion	(JW5503)	mutant	72	hour	biofilm	grown	
on	silicone	coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	
bars	represent	standard	error	(n=	6)	
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Figure	22	Hoechst	33342	assay	performed	on	acrB	deletion	(JW0451)	mutant	72	hour	biofilm	grown	
on	silicone	coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	
bars	represent	standard	error	(n=	6)	
	
	
Figure	23	Hoechst	33342	assay	performed	on	acrA	deletion	(JW0452)	mutant	72	hour	biofilm	grown	
on	silicone	coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	
bars	represent	standard	error	(n=	6)	
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Figure	24	Hoechst	33342	assay	performed	on	emrA	deletion	(JW2660)	mutant	72	hour	biofilm	grown	
on	silicone	coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	
bars	represent	standard	error	(n=	6)	
	
Figure	25	Hoechst	33342	assay	performed	on	emrB	deletion	(JW2661)	mutant	72	hour	biofilm	grown	
on	silicone	coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	
bars	represent	standard	error	(n=	6)	
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Figure	26	Hoechst	33342	assay	performed	on	emrE	deletion	(JW5031)	mutant	72	hour	biofilm	grown	
on	silicone	coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	
bars	represent	standard	error	(n=	6)	
	
	
Figure	27	Hoechst	33342	assay	performed	on	ompR	deletion	(JW3368)	mutant	72	hour	biofilm	grown	
on	silicone	coupons	treated	with	CCCP,	PAβN	and	capsaicin	for	15	min	prior	to	measurement.	Error	
bars	represent	standard	error	(n=	6)	
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5.2.3	Efflux	pump	inhibitor	effect	on	biofilm	viability		
To	determine	effect	of	EPIs	on	E.	coli	wild	type	and	deletion	mutants,	biofilm	coupons	were	
treated	with	EPIs	for	either	15	min	or	24	hours	before	the	biofilm	was	removed	from	
coupons	and	serial	dilutions	performed.	Pour	plates	were	performed	from	serial	dilutions.	
Table	4	shows	viability	in	response	to	EPI	treatment,	the	data	is	presented	as	reduction	Log10	
+1	cfu/coupon	compared	to	control	biofilms.	Mostly	the	EPIs	gave	moderate	reductions	in	
viability	though	tolC	did	show	decreases	up	to	2.85	Log10	+1	cfu/coupon	indicating	that	the	
EPIs	showed	some	toxicity	to	the	cell	biofilms.		There	was	an	increase	in	reduction	for	all	
biofilms	treated	with	PAβN	and	CCCP	the	longer	the	biofilm	was	exposed	to	the	EPI.	
Capsaicin	caused	a	significant	decrease	in	cfu	for	acrB	deletion	and	emrA	deletion	from	15	
min	to	24	hours,	however	this	was	not	observed	for	wild	type,	tolC	deletion	and	acrA	
deletion.		
Table	4	Efflux	pump	inhibitor	effect	on	cell	counts	per	coupon.	Reduction	Log10	+1	cfu/	coupon	from	
biofilm	control	plate	counts.		
Treatment		 Strain	(Reduction	Log10	+1	cfu/	coupon)	
	
Deletion	mutant		
Wild	type	 TolC	 AcrB	 AcrA	 EmrA	
	 15min	 6hr		 15min		 6hr	 15min		 6hr	 15min		 6hr	 15min		 6hr	
	
Control	
	 5.43*	 5.73*	 5.61*	 4.68*	 5.19*	 6.15*	 5.50*	 6.51*	 6.19	 6.65*	
CCCP	
	 0.12	 1.07	 0.45	 2.25	 -0.09	 0.96	 0.39	 0.88	 0.05	 0.72	
PAβN		
	 0.16	 1.80	 1.08	 2.85	 0.05	 1.08	 0.58	 1.03	 0.85	 1.81	
Capsaicin	
	 0.20	 0.21	 0.56	 0.66	 0.12	 1.12	 0.17	 0.31	 0.25	 1.13	
*=	Actual	count		
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5.3	Efflux	pump	inhibitor	and	antibiotic	combination	effect	on	efflux	pump	using	
Nile	red	real	time	efflux	pump	assay		
The	Nile	red	real	time	efflux	pump	assay	was	also	used	in	this	research	project	to	assess	
combinations	of	EPIs	and	antibiotics	on	the	efflux	pump	activity	of	biofilms.	It	was	also	used	
to	assess	the	substrate	competition	between	antibiotic	treatments	and	EPI	treatments.		
The	accumulation	of	Nile	red	represented	by	fluorescence	was	more	than	2x	higher	in	E.	coli	
wild	type	biofilms	(figure	28)	compared	to	what	was	recorded	for	any	of	the	deletion	mutant	
strains	biofilm	(figure	29-35).			
Fluorescent	profiles	observed	in	figure	31	for	the	acrB	deletion	mutant	showed	that	there	
was	evidence	of	PAβN	overwhelming	the	CCCP	to	which	the	biofilm	had	been	exposed.	
However,	there	was	some	overlapping	of	the	error	bars,	so	this	may	not	be	a	significant	
difference	between	the	two	samples.	Rifampicin	(Figure	31	b)	appeared	to	overcome	CCCP	
at	approximately	2500-seconds.	There	was	no	indication	that	capsaicin	was	able	to	
overcome	the	CCCP	as	it	had	a	similar	level	of	Nile	red	accumulation	to	the	control	for	the	
acrB	deletion.	AcrA	deletion	mutant’s	accumulation	of	Nile	red	was	lower	for	all	treatments	
it	was	exposed	to	compared	to	the	control	(figure	32).		
Fluorescent	profiles	for	ompR	deletion,	an	outer	membrane	protein	regulator,	were	higher	
for	all	antibiotics	when	compared	to	the	control.	This	was	especially	noticeable	for	nalidixic	
acid	(figure	35	d)	where	Nile	red	accumulation	was	double	that	obtained	for	the	control.	
Capsaicin	treatment	did	not	inhibit	efflux	of	Nile	red	of	the	ompR	deletion	mutant.			
EmrA	deletion	biofilm	was	most	responsive	to	rifampicin.	The	fluorescent	profile	indicates	
that	it	was	overcoming	CCCP	at	2500	seconds;	this	was	observable	in	the	level	of	Nile	red	
accumulating	in	the	sample	overtaking	the	control	sample	at	this	point.	Ampicillin	(figure	32	
a)	had	a	higher	fluorescent	profile	than	the	Control,	while	combinations	of	nalidixic	acid	and	
Gemma	Deakin	17117500		
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both	PAβN	and	capsaicin	gave	very	low	fluorescent	profiles.	This	indicated	efflux	of	Nile	red	
was	not	inhibited	as	much	as	the	control	for	emrA.	
Figure	33,	which	graphs	fluorescent	profiles	for	the	emrB	deletion	mutant,	showed	that	the	
PAβN	treatment	had	low	Nile	red	accumulation	in	comparison	to	the	control;	PAβN	in	
combination	with	nalidixic	acid	(figure	33	d),	however,	had	a	similar	level	of	accumulation	to	
the	control	of	emrB	deletion.	Rifampicin	and	PAβN	also	appears	to	start	to	overwhelm	the	
CCCP	however	the	standard	error	bars	were	not	substantially	different.	
The	fluorescence	obtained	for	emrE	deletion	(figure	34)	was	low	fluorescence	and	therefore	
indicated	low	Nile	red	accumulation	in	all	treatments	in	comparison	to	the	control.	This	
result	indicated	that	none	of	the	treatments	were	able	to	overwhelm	the	CCCP	and	have	a	
greater	effect	on	inhibition	of	the	efflux	pumps	of	this	particular	biofilm.		
The	tolC	deletion	mutant,	figure	29	a,	shows	that	the	combination	treatment	
ampicillin/PAβN	had	a	slightly	higher	level	of	Nile	red	than	the	control.	Rifampicin	and	PAβN	
(figure	20b)	also	had	a	higher	fluorescent	profile	than	the	control.	Combination	of	
rifampicin/capsaicin	had	a	similar	profile	to	the	control.	PAβN	treatment	on	its	own	had	a	
lower	level	of	florescence	and	therefore	a	lower	level	of	Nile	red	accumulation	than	the	
control	and	the	combination	of	PAβN	and	any	of	the	antibiotics.		
There	is	no	significant	substrate	competition	of	capsaicin	observable	for	any	of	the	deletion	
mutant	strains	except	for	tolC	deletion	(figure	29)	and	acrA	deletion	(figure	31).	Deletion	
mutants’	levels	of	Nile	red	accumulation	are	low	for	all	treatments	except	for	tolC	deletion	
mutant	and	acrA	deletion	mutant	which	had	a	similar	level	of	fluorescence	observed	for	
both	mutants	to	the	controls.
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Figure	28	Nile	red	real	time	efflux	pump	assay	performed	on	tolC	deletion	(JW5503),	72hr	old	biofilm	grown	on	stainless	steel	coupons	treated	with	antibiotics,	EPIs	and	Fluorophore	
for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	cycles	paused	and	glucose	added	at	600	seconds.	Fluorescence	cycles	resumed	at	1000	cycles.	a)	Ampicillin	treatment	
b)	Rifampicin	treatment	c)	Chloramphenicol	treatment	d)	Nalidixic	Acid	treatment.	Error	bars	represent	standard	error	(n=	6)	
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Figure	29	Nile	red	real	time	efflux	pump	assay	performed	on	AcrB	deletion	(JW0451),	72hr	old	biofilm	grown	on	stainless	steel	coupons	treated	with	antibiotics,	EPIs	and	Fluorophore	
for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	cycles	paused	and	glucose	added	at	600	seconds.	Fluorescence	cycles	resumed	at	1000	cycles.	a)	Ampicillin	treatment	
b)	Rifampicin	treatment	c)	Chloramphenicol	treatment	d)	Nalidixic	Acid	treatment.	Error	bars	represent	standard	error	(n=	6)	
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Figure	30	Nile	red	real	time	efflux	pump	assay	performed	on	acrA	deletion	(JW0452),	72hr	old	biofilm	grown	on	stainless	steel	coupons	treated	with	antibiotics,	EPIs	and	Fluorophore	
for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	cycles	paused	and	glucose	added	at	600	seconds.	Fluorescence	cycles	resumed	at	1000	cycles.	a)	Ampicillin	treatment	
b)	Rifampicin	treatment	c)	Chloramphenicol	treatment	d)	Nalidixic	Acid	treatment.	Error	bars	represent	standard	error	(n=	6)	
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Figure	31	Nile	red	real	time	efflux	pump	assay	performed	on	emrA	deletion	(JW2660),	72hr	old	biofilm	grown	on	stainless	steel	coupons	treated	with	antibiotics,	EPIs	and	Fluorophore	
for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	cycles	paused	and	glucose	added	at	600	seconds.	Fluorescence	cycles	resumed	at	1000	cycles.	a)	Ampicillin	treatment	b)	
Rifampicin	treatment	c)	Chloramphenicol	treatment	d)	Nalidixic	Acid	treatment.	Error	bars	represent	standard	error	(n=	6)	
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Figure	32	Nile	red	real	time	efflux	pump	assay	performed	on	emrB	deletion	(JW2660),	72hr	old	biofilm	grown	on	stainless	steel	coupons	treated	with	antibiotics,	EPIs	and	Fluorophore	
for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	cycles	paused	and	glucose	added	at	600	seconds.	Fluorescence	cycles	resumed	at	1000	cycles.	a)	Ampicillin	treatment	
b)	Rifampicin	treatment	c)	Chloramphenicol	treatment	d)	Nalidixic	Acid	treatment.	Error	bars	represent	standard	error	(n=	6)	
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Figure	33	Nile	red	real	time	efflux	pump	assay	performed	on	emrE	deletion	(JW5031),	72hr	old	biofilm	grown	on	stainless	steel	coupons	treated	with	antibiotics,	EPIs	and	Fluorophore	
for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	cycles	paused	and	glucose	added	at	600	seconds.	Fluorescence	cycles	resumed	at	1000	cycles.	a)	Ampicillin	treatment	
b)	Rifampicin	treatment	c)	Chloramphenicol	treatment	d)	Nalidixic	Acid	treatment.	Error	bars	represent	standard	error	(n=	6)	
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Figure	34	Nile	red	real	time	efflux	pump	assay	performed	on	ompR	deletion	(JW3368),	72hr	old	biofilm	grown	on	stainless	steel	coupons	treated	with	antibiotics,	EPIs	and	Fluorophore	
for	4	hours	prior	to	suspension	and	measurement.	Fluorescence	cycles	paused	and	glucose	added	at	600	seconds.	Fluorescence	cycles	resumed	at	1000	cycles.	a)Ampicillin	treatment	
b)Rifampicin	treatment	c)Chloramphenicol	treatment	d)Nalidixic	Acid	treatment.	Error	bars	represent	standard	error	(n=	6)	
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5.4	Effect	of	Treatments	on	Viablility	of	Biofilms		
To	determine	the	effect	of	combinations	of	EPIs	and	antibiotics	on	the	survival	of	E.	coli,	24-
hour	biofilms	were	treated	for	6	hours	with	combinations	of	antibiotics	and	EPIs;	serial	
dilutions	were	then	performed	and	plated.	Log10	CFU	was	calculated	for	each	of	the	
treatments	to	which	the	strains	were	exposed.	Cfu	was	calculated	per	mL	of	PBS	diluent,	and	
converted	to	CFU	per	coupon.	The	limit	of	detection	for	all	treatments	was	calculated	to	be	
1.5	Log10	CFU/	coupon.		
The	amount	of	biofilm	produced	by	each	of	the	deletion	mutants	did	have	some	slight	
variation	(Table	5).	However	only	the	TolC	deletion	showed	diminished	biofilm	formation,	it	
had	the	lowest	cell	count	of	the	controls.	This	indicated	that	the	single	deletion	did	not	have	
an	effect	on	the	other	deletion	mutant’s	ability	to	form	a	biofilm.
E.	coli	wild	type	shows	that	combinations	of	nalidixic	acid/CCCP,	chloramphenicol/PAβN	was	
most	efficient	in	reducing	colony	counts.	Nalidixic	acid	on	its	own	reduced	numbers	by	
approximately	2.5	Log10	CFU/coupon	(figure	37).	Ampicillin	reduced	CFU	by	approximately	2	
Log10	CFU/coupon	when	in	combination	with	an	inhibitor	on	its	own	reduction	was	only	1	
Log10	CFU/coupon	(table	4).		
TolC	deletion	when	treated	with	combinations	of	PAβN	and	all	antibiotics	were	effective	in	
reducing	Log10	CFU/coupon	in	comparison	to	the	control	(table	5).	They	gave	total	reduction	
below	the	limit	of	detection	of	1.5	Log10	CFU/coupon.	There	was	also	some	noticeable	
increase	in	inhibition	with	combinations	of	CCCP/chloramphenicol	and	CCCP/nalidixic	acid	as	
well	as	capsaicin/chloramphenicol	and	capsaicin/nalidixic	acid.	Combinations	of	CCCP	and	
antibiotics	were	not	as	effective	in	reducing	Log10	CFU/coupon	for	acrB	deletion	mutants	
biofilm	as	they	were	for	wild	type	biofilm	(figure	38).		
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AcrB	deletion	mutant	biofilm	appears	to	be	particularly	sensitive	to	PAβN,	the	largest	cell	
count	reduction	was	observed	for	combinations	of	PAβN	and	all	antibiotics.	Similar	to	acrB	
deletion	(figure	31)	there	was	a	reduction	greater	the	2	Log10	CFU/coupon	for	combinations	
of	CCCP/chloramphenicol,	CCCP/nalidixic	acid,	capsaicin/chloramphenicol	as	well	as	
capsaicin/nalidixic	acid.		
EmrA	deletion	biofilm	has	the	greatest	reduction	in	CFU	for	ampicillin	and	PAβN,	
chloramphenicol/PAβN,	and	nalidixic	acid/PAβN	treatments.	There	was	a	2.5	Log10	
CFU/coupon	reduction	for	chloramphenicol/CCCP	treatment	in	comparison	to	the	control	
treatment,	however	this	was	still	higher	than	the	CFU	obtained	for	the	same	treatment	
performed	on	E.	coli	wild	type	biofilm.		
For	acrA	deletion	biofilm,	the	most	notable	reduction	in	CFU	between	the	control	and	a	
treatment	was	for	Chloramphenicol/PAβN	(table	5).	Nalidixic	acid/capsaicin	caused	a	5	Log10	
CFU/coupon	reduction	in	CFU	in	comparison	to	both	the	control	and	capsaicin	treatment	on	
their	own	(figure	41).	There	was	a	reduction	following	nalidixic	acid	and	PAβN	treatment	of	
approximately	4	log10	(Table	5).	This	was	very	similar	to	the	CFU	obtained	for	the	same	
treatment	performed	on	E.	coli	wild	type.		
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Table	5	Log10	+1	cfu/	coupon	reduction	from	controls	of	each	strain	viability	enumeration.	
Controls	Log10	+1	cfu/	coupon	included	for	reference.	Reduction	figures	identical	to	control	
indicates	100%	reduction.			
Treatment		 Strain	(Reduction	Log10	+1	cfu/	coupon)	
	
Deletion	mutant		
Wild	type	 tolC	 acrB	 acrA	 emrA	
Control	
	
5.73*	 4.68*	 6.15*	 6.51*	 6.65*	
CCCP	
	
1.07	 2.25	 0.96	 0.88	 0.72	
PAβN		
	
1.80	 2.85	 1.08	 1.03	 1.81	
Capsaicin	
	
0.21	 0.66	 1.12	 0.31	 1.13	
Ampicillin	
	
0.96	 0.65	 0.53	 0.82	 1.36	
Ampicillin	&	CCCP	
	
2.55	 3.14	 1.55	 1.21	 1.75	
Ampicillin	&	PAβN	
	
3.03	 4.68t	 6.15t	 1.98	 6.65t	
Ampicillin	&	Capsaicin	
	
3.03	 4.68t	 1.51	 0.57	 1.47	
Rifampicin	
	
0.83	 1.81	 1.30	 0.57	 1.36	
Rifampicin	&	CCCP	
	
1.68	 2.38	 1.63	 0.88	 1.61	
Rifampicin	&	PAβN	
	
3.03	 2.85	 6.15	 1.32	 1.95	
Rifampicin	&	
Capsaicin	
2.55	 2.67	 1.09	 0.60	 1.54	
Chloramphenicol	
	
0.74	 2.31	 0.41	 0.78	 1.30	
Chloramphenicol		&	
CCCP	
3.03	 4.68t	 2.32	 1.29	 2.65	
Chloramphenicol	&	
PAβN	
5.73	 4.68t	 6.15t	 6.51t	 6.65t	
Chloramphenicol	&	
Capsaicin	
3.03	 4.68t	 2.63	 1.98	 2.05	
Nalidixic	Acid	
	
2.55	 0.50	 0.76	 0.47	 0.78	
Nalidixic	Acid	&	CCCP	
	
1.88	 4.68t	 2.15	 1.29	 2.05	
Nalidixic	Acid	&	PAβN	
	
2.55	 4.68t	 6.15t	 2.98	 6.65t	
Nalidixic	Acid	&	
Capsaicin	
1.26	 2.67	 2.63	 1.94	 2.01	
*	=	Actual	counts	t	=	total	reduction,	actual	count	is	0	below	limit	of	detection	
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a) 	
b) 	
c) 	
d) 	
Figure	35	E.	coli	K12	Wild	type	a)	control	b)	CCCP	Treatment	c)	PAβN	Treatment	d)	Capsaicin	
Treatment.	Limit	of	detection	is	1.5	Log10	cfu/coupon		
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a) 		 	
b) 		 		
c) 			 			
d) 		 	
Figure	36	E.	coli	tolC	deletion	(JW5503)	a)	control	b)	CCCP	Treatment	c)	PAβN	Treatment	d)	
Capsaicin	Treatment.	Limit	of	detection	is	1.5	Log10	cfu/coupon	
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a) 	
b) 			
c) 	
d) 	
Figure	37	E.	coli	acrB	deletion	(JW0451)	a)	control	b)	CCCP	Treatment	c)	PAβN	Treatment	d)	
Capsaicin	Treatment.	Limit	of	detection	is	1.5	Log10	cfu/coupon		
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a) 	
b) 	
c) 	
d) 	
Figure	38	E.	coli	emrA	deletion	(JW2660)	a)	control	b)	CCCP	Treatment	c)	PAβN	Treatment	d)	
Capsaicin	Treatment.	Limit	of	detection	is	1.5	Log10	cfu/mL	
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a) 	
b) 	
c) 	
d) 	
Figure	39	E.	coli	acrA	deletion	(JW0452)	a)	control	b)	CCCP	Treatment	c)	PAβN	Treatment	d)	
Capsaicin	Treatment.	Limit	of	detection	is	1.5	Log10	cfu/coupon	
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	 	 6.	DISCUSSION	
	
Bacterial	biofilms	are	heavily	associated	with	the	infectious	state,	especially	with	recurrent	
infections	(1).	The	prevalence	of	antibiotic	resistant	bacteria	has	increased	over	the	last	20	
years	and	continues	to	do	so	(43,	44);	it	is	for	this	reason	that	we	need	a	greater	
understanding	of	infectious	bacterial	biofilms	and	how	they	respond	to	antibiotics.	This	
research	project	aimed	to	investigate	E.	coli	biofilms	and	what	effect	efflux	pumps	have	on	
their	antibiotic	sensitivity.		This	investigation	focused	on	the	use	of	two	efflux	pump	assays	
and	enumeration	of	survival	by	treating	and	plating.	
The	first	assay	used	was	Nile	red	real	time	efflux	pump	assay,	originally	developed	for	
planktonic	cultures	and	was	adapted	for	biofilm	cultures	in	this	project.	The	modifications	
made	for	biofilms	included	culturing	biofilms	in	a	CDC	biofilm	reactor	for	72	hours	and	
washing	coupons	with	PBS	in	a	petri	dish.	The	biofilm	coupons	were	exposed	the	Nile	red	
dye	and	potential	competitors	in	a	24	well	microtiter	plate	and	incubated	for	the	same	
amount	of	time	as	the	original	protocol.	The	biofilms	were	then	removed	from	the	coupons	
via	sonication	in	2	mL	PBS,	each	sample	was	then	plated	into	a	96	well	black-bottomed	plate	
and	fluorescence	was	read.			
Fluorescence	levels,	which	represent	the	amount	of	Nile	red	accumulation,	recorded	for	
biofilms	were	much	lower	than	those	obtained	for	biofilm	cultures.	This	is	most	likely	due	to	
lower	concentration	of	cells	in	the	biofilm	in	comparison	to	the	concentration	that	was	
obtained	during	centrifugation	steps	of	the	planktonic	method	(data	not	shown).	Another	
aspect	of	the	adaptions	that	may	influence	the	lower	fluorescence	levels	is	that	with	the	
planktonic	cells,	the	cells	took	up	the	majority	of	Nile	red	dye	prior	to	centrifugation.		During	
the	washing	steps	that	were	substituted	for	centrifugation	of	the	biofilm	it	was	noticed	that	
Gemma	Deakin	17117500		
81	|	P a g e 	
considerable	amount	of	the	Nile	red	dye	was	not	taken	up	by	the	biofilm	cells.	Not	only	were	
there	fewer	bacterial	cells	but	there	may	have	been	less	dye	in	the	samples	that	
fluorescence	was	measured	from,	resulting	in	the	observable	difference	in	fluorescence	
between	biofilm	and	planktonic	samples.			
The	Nile	red	accumulation	represented	by	fluorescent	readings	observable	in	the	planktonic	
wild	type	samples	differ	from	those	obtained	for	wild	type	biofilm	and	both	planktonic	and	
biofilms	of	TolC	deletion	mutant.	The	wild	type	planktonic	sample	fluorescence	pattern	was	
characteristic	of	those	reported	by	Bohnert	et	al.	(123)	and	other	users	of	the	Nile	red	real	
time	efflux	pump	assay	(129,	130).	This	is	the	dramatic	drop	in	fluorescence	after	the	
addition	of	glucose.	The	glucose	energises	the	sample’s	efflux	pumps	at	which	time	they	
start	to	expel	the	Nile	red	fluorophore.	This	however	is	not	what	was	observed	for	either	the	
wild	type	biofilm	or	the	deletion	mutants’	biofilms	or	for	the	mutant	planktonic	tolC	
deletion.	The	biofilm	cells	appear	to	start	accumulating	the	dye	when	reenergised	causing	
the	observable	increase	in	fluorescence.	Reasons	for	this	occurring	could	be	attributed	to;	
the	nature	of	biofilms	i.e.	that	it	takes	active	metabolism	for	both	influx	and	efflux	of	the	
fluorophore,	or	there	being	too	high	concentration	of	CCCP	to	the	number	of	cells	in	the	
biofilm	or	the	planktonic	cells	i.e.	that	the	concentration	of	glucose	used	was	not	high	
enough	to	overcome	the	CCCP	and	initiate	efflux.	The	pattern	of	biofilm	efflux	from	the	
deletion	mutants	behaved	similarly	to	the	wild	type	biofilm	i.e.	efflux	was	impaired	resulting	
in	a	higher	accumulation.		
The	second	efflux	pump	activity	assay,	which	utilises	the	fluorescent	dye	Hoechst	33342,	as	
described	by	Coldham	et	al.	(116),	was	a	modification	of	previous	methods	using	ethidium	
bromide	(EtBr).	They	found	that	the	Hoechst	33342	assay	was	a	more	sensitive	and	specific	
assay	for	MDR	Salmonella	mutants	than	Ethidium	Bromide	(EtBr),	a	traditionally	used	dye	
(116)	that	was	reflected	in	the	preliminary	testing	of	the	current	research	project	(data	not	
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shown).		In	addition	to	being	inexpensive	and	relatively	rapid,	Hoechst	33342	is	a	safer	
alternative	to	EtBr	which	binds	to	DNA	in	an	intercalation	form	between	base	pairs(131).		It	
is	now	not	used	frequently	in	microbiology	and	molecular	biology	laboratories	as	the	dye	
causes	cellular	neurotoxicity	when	tested	on	rats	(118)	and	has	mutagenicity,	carcinogenicity	
and	teratogenicity	potentials	(119).	Hoechst	33342	is	readily	taken	up	by	living	cells	and	is	
nontoxic	(120).		Hoechst	dyes	bind	to	the	minor	groove	of	the	DNA	helix	and	has	an	affinity	
for	AT-rich	regions	of	four	or	more	base	pairs	(122).		The	dye	is	known	to	be	a	substrate	for	
many	MDR	transporters	specifically	those	controlled	by	the	global	regulator	protein	MarA.	
Coldham	et	al.	(116)	found	that	when	Salmonella	typhimurium	mutants	missing	genes	for	
the	AcrAB-TolC	were	tested	with	Hoechst	33342,	there	was	a	significant	increase	in	
accumulation	of	the	dye	leading	to	the	deduction	that	Hoechst	33342	is	a	substrate	of	the	
AcrAB-	TolC	efflux	pump.	This	pump	belongs	to	the	RND	family	and	uses	a	proton	gradient	to	
drive	substrate	from	the	binding	pocket	in	the	AcrAB	outside	the	cell	via	TolC	(116).	AcrAB-
TolC	is	a	clinically	significant	efflux	pump	in	E.	coli.	It	is	for	this	reason	that	this	assay	was	
implemented	in	the	research	as	a	method	of	assessing	efflux	pump	activity.	The	results	of	
the	current	research	project	indicate	that	Hoechst	33342	is	not	limited	to	transport	via	the	
AcrAB-TolC	pump.	Single	deletion	mutants	other	than	acrA,	acrB,	and	tolC	deletion	mutant	
biofilms	all	exhibited	differences	in	the	levels	of	Hoechst	33342	accumulated.	This	
observation	indicates	that	it	is	not	the	only	pump	involved	in	the	exportation	of	Hoechst	
33342	and	that	the	deletions	of	emrA,	emrB,	emrE	and	ompR	all	influenced	the	amount	of	
dye	accumulated	and	expelled	by	the	biofilm	cells.	
The	adjustments	made	in	this	study	to	the	protocol	that	was	published	by	Coldham	et	al.	
(116)	resulted	in	observable	trends	similar	in	biofilm	cells	to	the	planktonic	cells	undergoing	
the	same	treatments	(figure	21).	The	exponential	difference	in	the	levels	of	fluorescence	can	
be	potentially	attributed	to	either	the	cell	count	difference	between	biofilm	and	planktonic	
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cells,	as	there	were	1000X	cells	in	the	broth	culture	than	was	sonicated	off	the	silicone	
coupons	(data	not	shown).	It	may	also	have	been	due	to	the	nature	of	biofilms.	As	previously	
mentioned	they	are	metabolically	slower	than	their	rapidly	growing	planktonic	counterparts	
(1,	3)	and	therefore	import	and	export	the	substrates	such	as	the	Hoechst	33342	dye	more	
slowly	than	the	planktonic	cells.		
The	Hoechst	33342	efflux	pump	assay	performed	on	the	deletion	mutants	(figure	20-27)	
gave	similar	patterns	of	fluorescence	i.e.	PAβN	and	capsaicin	consistently	caused	a	higher	
level	of	fluorophore	accumulation	than	the	control	and	CCCP	treatment.	The	increased	
accumulation	of	Hoechst	33342	indicates	that	the	efflux	pump	has	been	inhibited,	and	
inhibition	in	efflux	pump	activity	was	found	in	some	treatments	to	correlate	with	an	effect	
on	the	viability	of	that	biofilm	when	treated	in	combination	with	antibiotics.	For	example,	
the	pattern	of	Hoechst	33342	accumulation	reflects	the	survival	of	acrA	deletion	mutants	
when	treated	with	antibiotics.	When	cells	of	acrA	deletion	mutant	were	treated	with	
inhibitors	in	combination	with	nalidixic	acid	and	chloramphenicol,	the	survival	patterns	
mimicked	the	order	of	the	EPI	treatments	seen	in	fluorescent	profiles	observed	in	figure	23.	
Similarly	TolC	deletion	biofilms	also	exhibited	this	pattern	in	reaction	to	ampicillin	and	EPI	
combinations	(figure	21	and	table	5).	This,	however,	was	not	what	was	observed	for	acrB	
and	emrA	deletion	mutant	biofilms.		Hoechst	33342	accumulations	did	not	show	any	trends	
that	were	reflected	in	survival	in	presence	of	antibiotics.		The	viability	of	biofilms	after	6	hour	
exposure	to	treatments	were	not	performed	on	all	deletion	mutants	24	hour	biofilms		(table	
5)	due	to	time	limitations	of	this	research	project.		Extended	use	of	Hoechst	33342	efflux	
assay	in	combination	with	viability	may	be	implemented	in	the	future	as	a	preliminary	test	to	
determine	which	EPIs	would	be	most	effective	on	particular	E.	coli	strains.	CCCP	appears	to	
affect	the	deletion	mutants	unusually	in	that	it	appears	that	in	the	Hoechst	assay	it	limits	the	
ability	of	the	bacterial	biofilm	to	uptake	the	dye.	CCCP	is	a	proton	uncoupler	(110)	and	the	
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data	obtained	in	this	research	suggests	that	it	was	also	having	an	effect	on	the	movement	of	
substances	into	the	biofilm	cells.		
	When	comparing	Nile	red	results	to	those	obtained	for	Hoechst	33342-efflux	assay,	there	
are	some	similarities	between	the	two	assays.	The	differences	observed	in	Hoechst	3342	and	
Nile	red	assays	between	deletions	and	wild	type	biofilms	are	not	likely	due	to	a	difference	in	
cell	counts.	Table	4	shows	that	the	cell	count	per	coupon	(Log10	+1	CFU/	coupon)	does	not	
differ	dramatically	between	the	mutants	and	the	wild	type.	This	indicates	that	the	results	
that	were	obtained	are	not	due	to	differing	cell	counts.	This	result	is	contrary	to	what	was	
observed	by	Matsumura	et	al.	(3)	who	observed	a	reduction	in	biofilm	formation	for	deletion	
mutants	acrA,	acrB,	emrE,	emrB,	emrA	(3).	AcrB	deletion	mutant	biofilm	in	the	current	
research	project	responded	consistently	to	both	Hoechst	33342	and	Nile	red	when	exposed	
to	EPIs;	figures	31	and	22	have	similar	fluorescent	profiles.	The	rate	of	accumulation	and	
therefore	efflux	was	relatively	steady	as	demonstrated	by	the	lack	of	incline	or	decline	in	the	
profiles.	The	order	of	accumulation	in	treatments	was	however	different.	Accumulation	of	
Hoechst	was	highest	in	capsaicin	treatment	and	PAβN	gave	the	highest	accumulation	of	Nile	
red.	This	trend	was	consistent	with	all	deletion	mutants	and	the	wild	type.	The	level	of	
fluorophore	accumulation	differed	between	the	assays.	The	capsaicin	and	PAβN	treatments	
accumulated	the	highest	levels	of	Hoechst	relatively	consistently	between	the	strains.	
Accumulation	of	Nile	red	appeared	to	be	slightly	more	differential;	deletion	mutant	acrB	was	
most	similar	to	the	wild	type,	which	was	not	the	case	for	Hoechst	33342	assay,	in	which	
ompR	was	the	most	like	wild	type.		OmpR	deletion	being	similar	to	the	wild	type	is	most	
likely	due	to	it	having	limited	effect	on	the	efflux	of	Nile	red.	It	has	been	suggested	to	
positively	control	the	expression	of	AcrAB-TolC	by	Raczkowska	et	al.	(126),	however,	this	
finding	was	not	reinforced	by	the	findings	of	the	current	research	project.		
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Nile	red	accumulation	and	order	was	very	similar	for	acrA	and	tolC	deletion	mutants.		
Despite	belonging	to	the	same	pump,	TolC	and	AcrA	have	distinctly	different	roles	(132).	
TolC	is	responsible	for	mediating	transport	from	the	periplasm	to	the	outside	of	the	cell,	and	
the	role	of	AcrA	lies	in	supporting	the	function	of	AcrB	(133).	The	similarity	in	accumulation	
of	biofilms	lacking	these	particular	transporter	components	seems	to	suggest	that	the	
deletion	results	in	a	similar	interference	to	the	efflux	mechanism	in	exporting	Nile	red	from	
the	bacterial	cells.	
The	differences	in	accumulation	of	the	fluorophore	Nile	red	between	treatments	of	
combination	antibiotics	and	EPIs,	and	the	controls	of	each	biofilm	wild	type	or	deletion	
mutant	are	interesting.	Typically	the	control	had	a	higher	accumulation	than	the	biofilm	cells	
treated	with	antibiotic	and	EPI	combinations.	The	hypothesised	results	of	this	assay	would	
be	that	the	cells	treated	with	antibiotic	and	EPI	would	accumulate	more	fluorophore	than	
the	untreated	control,	but	this	was	not	what	was	observed.	The	biofilms	have	been	exposed	
to	the	antibiotics	for	a	period	of	4	hours,	which	in	a	planktonic	culture	may	be	enough	time	
for	a	bacterial	strain	to	develop	some	adaptive	resistance	(56).	However	this	assay	was	
performed	on	biofilms,	which	are	slow	growing	(9),	therefore	it	is	unlikely	that	adaptive	
resistance	was	the	cause	of	the	trends	in	accumulation	that	can	be	observed.	If	this	were	
occurring,	the	accumulation	observed	for	the	wild	type	would	not	be	expected.	It	is	more	
likely	that	the	antibiotic	and	EPI	combinations	have	had	a	dual	effect	on	both	influx	and	
efflux	in	the	biofilms.		
Rifampicin	is	a	broad-spectrum	antibiotic	that	targets	and	inhibits	bacterial	RNA	polymerase.	
Bacterial	strains	develop	resistance	to	rifampicin	quickly	therefore	it	has	been	restricted	to	
treating	tuberculosis	and	emergencies	(134).	Rifampicin	diffuses	freely	into	bacterial	cells	
and	does	not	require	active	metabolism	to	be	effective	against	bacterial	infections,	and	
hence	rifampicin	is	effective	against	both	slow-growing	and	non-replicating	cells	(14).		The	
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viability	data	(figure	36-40)	indicate	that	when	combined	with	EPIs	the	antibiotics	killing	is	
not	increased	significantly	as	was	observed	with	other	antibiotic	and	EPI	combinations.	This	
may	be	due	to	biofilm	cells	not	requiring	the	action	of	efflux	pumps	to	decrease	the	internal	
concentration	of	rifampicin.	Rifampicin	diffuses	freely	into	cells	(134)	and	it	is	possible	it	is	
also	capable	of	diffusing	out	of	the	cell.		
Ampicillin	is	a	cell	wall	inhibitor	that	does	not	kill	non-growing	cells;	its	rate	of	killing	has	
been	reported	as	being	proportional	to	the	rate	of	growth	of	the	bacterial	culture	it	is	being	
used	on	(135).		Its	mechanism	of	action	is	that	it	inhibits	transpeptidase,	which	is	an	enzyme	
that	is	required	for	cell	wall	synthesis.	The	inhibition	of	transpeptidase	causes	cell	death	by	
lysis.	Chloramphenicol	is	lipid	soluble,	so	it	is	able	to	diffuse	through	the	cell	wall.	It	is	a	
broad	spectrum	antibiotic	which	prevents	bacteria	growth	by	binding	to	the	ribosome	and	
preventing	protein	synthesis.	Nalidixic	acid	is	a	synthetic	quinolone	antibiotic	that	works	by	
interfering	with	and	inhibiting	DNA	synthesis	(136,	137).	These	antibiotics	were	chosen	for	
this	study	because	the	AcrAB-TolC	efflux	pump	system	plays	a	role	in	resistance	to	these	
drugs	(127).	The	EmrAB	is	known	to	be	resistant	to	Nalidixic	acid	(138)	and	similarly	EmrE	
contributes	to	resistance	to	EtBr	(139),	which	as	discussed	earlier	in	this	section,	is	a	
substrate	of	the	AcrAB-	TolC	system	(44).	With	this	knowledge	we	would	expect	that	single	
deletion	mutants	of	the	pumps	systems	treated	with	the	antibiotics	they	efflux	would	exhibit	
higher	accumulation	of	fluorophore	and	would	have	a	decreased	survival	than	the	wild	type	
treated	with	the	same	antibiotic.	We	would	also	expect	that	antibiotics	in	combination	with	
an	EPI	that	is	a	substrate	of	the	efflux	transporter	deletion	in	question	would	further	
increase	the	amount	of	accumulation	observed	and	there	would	be	a	greater	decrease.	This	
proved	correct	for	the	known	substrates	of	AcrB-TolC	in	regards	to	the	viability	and	when	
treated	with	EPIs	and	observed	accumulation	of	Hoechst.	However,	the	pattern	of	
accumulation	when	treated	with	combinations	of	antibiotics	and	EPIs	observed	with	Nile	red	
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accumulation	was	often	lower	than	when	treated	with	the	antibiotic	singly.	This	is	further	
evidence	that	the	EPIs	have	an	effect	on	influx	as	well	as	efflux.		
In	assessing	the	data	acquired	in	this	research	project	there	are	indications	that	in	some	
instances	capsaicin	is	a	more	effective	EPI	than	traditionally	used	PAβN	and	CCCP.	However,	
this	not	the	case	for	all	knockout	strains,	taking	this	into	account	capsaicin	has	marked	
effectiveness	against	efflux	transporter	proteins.	Capsaicin	is	not	well	established	as	an	EPI.	
It	was	first	studied	as	an	EPI	BY	Kalia	et	al.	(110)	who	determined	it	was	effective	against	
NorA	efflux	pump	of	S.	aureus.	In	the	current	research	project	it	was	tested	on	biofilms	of	a	
number	of	efflux	pump	deletion	mutants.		The	results	of	Hoechst	33342	efflux	pump	assay	
suggest	that	it	has	a	similar	profile	to	PAβN,	which	is	a	well-studied	EPI	that	has	been	
reported	at	concentrations	above	4	mg/mL	to	permeabilise	wild	type	E.	coli	outer	
membranes.	This	would	make	it	unsuitable	as	a	pharmacological	EPI	as	it	is	likely	to	target	
the	membranes	of	eukaryotic	cells	(104)	.	Capsaicin	behaved	similarly	to	PAβN,	which	could	
indicate	that	it	has	a	similar	mechanism	of	action.	PAβN	is	a	competitive	inhibitor	of	AcrAB-
TolC,	which	interferes	with	binding	of	antibiotics	to	the	efflux	pumps.		
It	has	been	suggested	that	PAβN	is	specific	only	to	AcrAB	efflux	pump	(140),	this	is	not	what	
the	results	of	the	current	research	project	indicated.	When	acrA	and	acrB	deletion	mutants	
were	treated	with	PAβN	there	was	an	observable	accumulation	of	Hoechst	33342	dye,	and	
there	was	a	reduction	in	the	viable	count	in	comparison	to	the	control.	These	results	indicate	
that	PAβNs	inhibitory	effect	on	efflux	pump	systems	is	not	exclusive	to	AcrAB.			
While	the	levels	of	fluorescence	were	similar	to	PAβN	the	survival	data	obtained	for	each	
deletion	mutant	were	not.	Capsaicin	reduced	the	CFU/	coupon	of	control	wild	type	by	only	
37.7%	and	deletion	mutants	tolC,	acrB,	acrA,	and	emrA	reduced	by	78.2%,	92.4%,	50.5%	and	
92.6%	respectively.	Compared	to	PAβN,	which	reduced	CFU/	coupon	by	90-99%	for	wild	type	
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and	each	deletion	mutant,	capsaicin	causes	a	lower	reduction	when	biofilms	are	treated	
solely	with	capsaicin	and	most	significantly	only	37.2%	reduction	is	observed	for	the	
functioning	efflux	E.	coli	wild	type.	This	result	indicates	that	if	capsaicin	is	having	a	
bactericidal	effect	as	a	result	of	membrane	permeablization	it	is	not	as	severe	as	the	effect	
of	PAβN;	more	study	is	required	to	determine	the	toxicity	effect	of	capsaicin.	Capsaicin,	
when	in	combination	with	antibiotics,	reduced	the	E.	coli	wild	type	biofilm	CFU/	coupon	by	
99.9%	with	ampicillin,	99.7%	with	rifampicin,	99.9%	with	chloramphenicol	and	94.5%	with	
nalidixic	acid.	This	is	a	higher	reduction	in	cell	count	than	the	antibiotics	on	their	own,	which	
suggests	capsaicin	may	be	EPI	of	E.	coli	biofilms	of	potential	clinical	significance.	
Nile	red	real	time	efflux	assay	gave	different	accumulations	of	fluorophore	than	those	
observed	in	Hoechst	33342.	In	both	assays	if	the	efflux	pump	has	been	inhibited	then	the	
dye	can	accumulate	in	the	cell,	therefore	fluorescence	is	a	representation	on	the	inhibition	
of	efflux	pumps.	As	the	two	assays	gave	different	accumulation	orders,	it	can	be	assumed	
each	gives	different	information	about	the	mechanism	of	efflux	pumps.	In	planktonic	cells	it	
shows	efflux	being	initiated	and	working	in	real	time	for	the	strain	being	used.	This	is	
potentially	being	identified	in	the	biofilms	as	well,	however	instead	of	efflux	being	initiated	
real	time	accumulation	is	initiated,	showing	the	biofilms	response	to	metabolites.	The	assay	
also	shows	substrate	competition	and	substrate	specificity.	The	results	indicated	that	Nile	
red	accumulation	was	commonly	highest	in	samples	treated	with	only	CCCP	or	with	samples	
treated	with	an	antibiotic	only.		This	is	likely	due	to	the	cells	response	to	antibiotics	i.e.	the	
cell	has	preference	for	expelling	antibiotics	over	the	Nile	red	dye,	allowing	it	to	accumulate	
in	the	cell.	This	indicates	that	in	this	particular	samples	that	there	is	higher	substrate	
specificity	for	the	antibiotics	over	the	dye	and	potentially	the	EPIs	that	they	are	treated	with.	
This	is	apparent	in	figure	14	b	in	which	there	is	a	higher	level	of	accumulation	in	samples	
treated	with	rifampicin	than	those	treated	with	capsaicin.		
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The	focus	of	this	research	project	was	to	assess	how	efflux	pumps	affect	the	sensitivity	of	E.	
coli	biofilms	to	antibiotics.	An	indication	of	this	is	the	results	obtained	for	tolC	deletion	
mutant.	TolC	is	an	outer	membrane	protein	that	is	a	key	component	in	a	number	of	efflux	
pump	systems	including	AcrAB-TolC	and	EmrAB-TolC.		Figure	31	shows	the	survival	of	tolC	
deletion	mutant	in	reaction	to	EPI	and	antibiotics.	There	was	a	reduction	of	>0.5	Log10	cfu	for	
all	antibiotic	treatments.	Combinations	of	antibiotics	and	EPI’s	caused	a	>	2	log10	cfu	
decrease	from	tolC	deletion	mutant	biofilm	untreated	control.	The	tolC	deletion	mutant	
control	biofilm	had	a	reduction	of	1	log10	cfu	compared	to	wild	type	control	biofilms.	In	
controls	of	the	other	deletion	mutants	the	viability	of	the	biofilm	cells	was	similar	or	higher	
than	the	wild	type	biofilm	cells.		This	suggests	that	tolC	is	involved	in	more	biological	
processes	than	just	antibiotic	evasion.	This	observation	is	consistent	with	the	literature	(78),	
which	reports	that	efflux	pumps	are	important	in	biological	process	of	waste	extrusion.	The	
reduced	numbers	of	log10	cfu	is	not	only	from	controls	but	can	also	be	observed	from	wild	
type	biofilms	exposed	to	the	same	combinations	of	antibiotics	and	EPI	of	>0.5	log10	cfu.	
Therefore	the	association	between	efflux	pump	inhibitors	and	the	antibiotic	sensitivity	of	
biofilms	is	that	without	functioning	efflux	pumps	the	biofilm	is	more	sensitive	to	antibiotics.		
Efflux	pump	single	gene	deletion	mutants	were	utilised	in	this	study	to	observe	the	efficiency	
of	EPIs	and	to	determine	the	effects	of	single	efflux	pumps	in	the	antibiotic	sensitivity	of	E.	
coli	biofilms.	Deleting	an	individual	efflux	pump	does	not	appear	to	affect	the	antibiotic	
sensitivity	of	the	biofilm	to	a	great	extent,	as	the	biofilms	of	the	mutants	appeared	no	more	
susceptible	to	antibiotics	than	the	wild	type.	However	when	the	biofilms	of	mutants	with	
disabled	efflux	pumps	were	exposed	to	an	EPI	and	an	antibiotic	there	was	a	greater	
reduction	in	viability	than	when	a	deletion	mutant	is	exposed	to	an	antibiotic	alone.	This	
suggests	that	it	is	the	effects	of	the	sum	of	the	many	efflux	pumps	that	E.	coli	has	that	result	
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in	the	observed	antibiotic	resistance	of	the	biofilm	rather	than	the	action	of	a	single	efflux	
pump.	Similarly	the	results	suggest	the	action	of	the	EPIs	was	across	several	efflux	pumps.	
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7.	CONCLUSIONS	AND	FUTURE	WORK	
7.1	Conclusions		
It	was	determined	in	this	research	project	that	the	antibiotic	sensitivity	of	E.	coli	biofilms	is	
influenced	by	the	presence	and	activity	of	efflux	pumps.	This	was	established	via	the	use	of	
efflux	pump	deletion	mutants	and	EPIs.		Specifically	table	5	suggests	that	when	the	function	
of	an	efflux	pump	system	in	a	biofilm	is	inhibited	there	is	a	decrease	in	viability	of	cells	in	
response	to	antibiotic	treatment.		
The	results	of	the	assays	and	viability	testing	performed	on	E.	coli	biofilms	suggest	that	the	
efflux	pump	activity	of	72-hour	E.	coli	biofilms	is	different	to	the	efflux	pump	activity	of	
planktonic	cell	cultures.	This	is	most	evident	in	the	results	obtained	for	Nile	red	real	time	
efflux	assay	for	wild	type	planktonic	culture	(figure	9).	The	planktonic	culture	in	response	to	
the	addition	of	glucose	rapidly	expels	the	Nile	red	fluorophore.	Whereas	the	biofilm	cultures	
response	to	the	addition	of	glucose	is	that	the	cells	appear	to	initiate	influx	and	
accumulation	of	the	Nile	red	fluorophore.		Differences	were	also	observed	between	E.	coli	
planktonic	and	biofilm	cultures	in	the	accumulations	of	Hoechst	33342	demonstrated	in	
figure	11.		
This	research	project	has	identified	that	the	Hoechst	33342	efflux	pump	assay	has	potential	
to	be	a	preliminary	EPI	efficiency	test.		The	results	of	this	research	project	indicates	that	the	
level	of	Hoechst	33342	accumulation	by	E.	coli	biofilm	cells	can	be	reflected	in	the	viability	of	
wild	type	E.	coli	biofilm	cells	when	treated	with	combinations	of	PAβN	and	capsaicin	in	
combination	with	antibiotics	ampicillin,	rifampicin	and	chloramphenicol	(figure	36).		
Optimization	of	this	method	for	biofilms	and	testing	it	with	more	EPIs	would	bring	
clarification	to	this	possibility.	Hoechst	33342	efflux	pump	assay	was	more	sensitive	test	for	
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efflux	pump	activity	than	the	Nile	red	real	time	efflux	pump	assay.	It	was	also	far	easier	to	
interpret	the	results	of	this	test.		
Capsaicin	is	a	novel	inhibitor	of	the	NorA	Staphylococcus	aureus	(110).	This	research	project	
has	determined	that	it	is	also	an	inhibitor	of	efflux	pump	activity	of	E.	coli	biofilms.	The	
Hoechst	33342	assay	has	determined	it	is	an	inhibitor	of	efflux	in	emrA,	emrB,	emrE,	acrA	
and	acrB	mutants.	It	was	most	effective	on	wild	type	E.	coli	biofilms	when	in	combination	
with	ampicillin;	increased	efficiency	in	antibiotics	was	observed	for	all	four	antibiotics	tested.		
Capsaicin	affects	the	fluorophore	accumulation	similarly	to	PAβN;	the	rate	and	amount	of	
Hoechst	33342	was	very	similar.	Therefore	capsaicin	is	likely	to	have	a	similar	mechanism	of	
action	to	PAβN,	which	inhibits	efflux	pumps	by	its	competitive	substrate	action	(104).	PAβN	
is	toxic	to	bacterial	strains;	it	permeabilises	membranes	at	concentrations	greater	than	
4mg/ml	(106).	Whether	PAβN	has	the	same	effect	on	eukaryotic	cells	has	not	been	tested,	
but	it	has	been	theorized	that	it	would	target	the	same	biological	processes	in	the	eukaryotic	
cells	(71)	and	it	has	been	reported	that	toxic	side	effects	limit	its	potential	therapeutic		use	
(141).	Capsaicin	did	not	have	a	toxic	effect	on	wild	type	E.	coli	biofilm.	It	only	reduced	the	
biofilm	by	0.2	Log10	cfu/ml.	This	indicates	that	it	is	not	toxic	and	as	a	naturally	occurring	
molecule	in	chillies,	it	is	a	mild	irritant	but	does	not	cause	cellular	death.	It	is	used	
pharmaceutically	to	alleviate	pain	associated	with	diabetic	neuropathy,	to	reduce	
incontinence	associated	with	bladder	hyperactivity	and	to	treat	post-operative	nausea	(142).	
It	is	for	this	reason	that	it	has	the	potential	to	be	a	clinically	significant	EPI	that	has	the	ability	
to	increase	the	efficiency	of	antibiotics	in	a	patient	without	side	effects.		
7.2	Future	work		
The	testing	of	the	research	question	was	limited	by	the	time	frame	of	the	project.	If	more	
time	were	available	there	are	a	number	of	further	studies	that	could	be	done	to	help	bring	
clarification	and	to	gain	a	better	understanding	of	the	results.	Better	understanding	could	be	
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achieved	by	the	comparison	of	results	to	E.	coli	mutants	that	overexpresses	different	efflux	
pump	systems	(143).	Other	single	dilution	mutants	could	also	be	used.	As	stated	earlier	E.	
coli	has	37	efflux	systems	(71).	Examining	the	effects	of	other	efflux	pump	single	dilution	
mutants	on	biofilm	antibiotic	sensitivity	could	help	to	clarify	the	mechanisms	involved.	These	
further	research	options	would	help	to	give	a	greater	understanding	of	the	effects	of	efflux	
pumps	on	antibiotic	sensitivity.		
	
The	development	of	the	efflux	pump	assays	for	biofilms	revealed	that	the	assays	were	
capable	of	demonstrating	the	efflux	pump	activity	of	biofilms.	The	Nile	red	real	time	efflux	
pump	assay	was	complex	and	difficult	to	interpret,	and	to	be	used	in	subsequent	efflux	
pump	activity	research	it	would	require	optimization	for	use	with	biofilms.	In	the	current	
study	the	Hoechst	33342	efflux	pump	assay	was	found	to	be	a	superior	method	for	
measuring	efflux	pump	activity	in	biofilms.	The	modifications	made	to	the	assay	for	biofilms	
require	testing	on	biofilms	of	other	bacterial	strains,	to	assess	if	its	ability	to	function	as	an	
efflux	pump	activity	assay	is	limited	to	only	E.	coli	biofilms.	The	assay	should	also	be	
conducted	with	a	wider	range	EPIs	to	determine	whether	the	assay	is	able	to	function	as	a	
preliminary	EPI	test	for	bacterial	strains.	The	results	suggest	that	it	may	give	some	
indications	about	which	EPIs	are	most	effective	in	reducing	the	viability	of	a	bacteria	strain	
when	in	combination	with	an	antibiotic.	Further	testing	is	required	to	determine	if	the	assay	
can	function	this	way.				
The	assays	and	viability	testing	was	performed	on	mature	biofilms	in	the	current	research	
project.	The	antibiotic	sensitivity	of	biofilms	at	different	growth	stages	is	not	well	
understood	and	repeating	the	experimentation	on	E.	coli	biofilms	in	different	growth	stages	
could	be	beneficial	in	contributing	to	the	body	of	knowledge	on	antibiotic	sensitivity	of	
biofilms.		The	results	of	this	research	project	expressed	some	interesting	reactions	of	the	
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single	deletion	mutants’	biofilms	to	antibiotics,	EPIs	and	combinations	of	both.	Most	notably	
acrA,	had	a	high	level	of	Hoechst	33342	accumulation	when	exposed	to	PAβN	and	this,	was	
not	reflected	in	viability	reduction	to	the	same	extent	as	viability	counts	for	wild	type	when	
treated	with	Nalidixic	acid.	The	results	imply	the	differences	are	due	to	the	mechanism	of	
efflux	pump	activity	but	the	mechanism	needs	further	investigation.	With	increased	time	
and	more	deletion	mutants,	our	understanding	of	the	relationship	between	single	genes,	
efflux	pump	activity	and	viability	of	a	biofilm	could	be	broadened.		
Due	to	the	limited	time	available,	capsaicin’s	effect	on	viability	was	not	determined	for	all	of	
the	E.	coli	single	dilution	mutants.	Capsaicin	from	the	results	appears	to	be	an	effective	EPI	
of	E.	coli	biofilms	with	potential	pharmacologically	significance.	Further	examination	of	
capsaicin	with	other	bacterial	strains,	as	well	as	with	a	wider	range	of	antibiotic	classes	
should	be	conducted	to	determine	if	it	is	a	clinically	significant	EPI.	While	not	necessarily	an	
important	step	in	determining	the	efficiency	of	capsaicin	as	an	EPI,	research	on	the	
molecular	mechanisms	of	capsaicin	as	an	EPI	is	limited	and	its	mechanism	of	action	has	yet	
to	be	identified.			
	
	
Gemma	Deakin	17117500		
95	|	P a g e 	
8.APPENDIX	
Table	6	Deletion	mutants	and	wild	type	15min	exposure	to	EPIs	and	antibiotics	viability	plate	counts.	
Treatment	
Log10	+1	cfu/coupon		
	
Deletion	Mutant	
E.	coli	
Wild	
type	
tolC	 acrB	 acrA	 emrA	 emrB	 emrE	 ompR	
Control	
	
5.43	 5.61	 5.19	 5.50	 6.19	 5.01	 4.87	 5.43	
CCCP	
	
5.30	 5.15	 5.28	 5.11	 6.13	 4.78	 4.70	 5.60	
PAβN		
	
5.26	 4.53	 5.14	 4.92	 5.34	 4.58	 4.43	 5.14	
Capsaicin	
	
5.22	 5.05	 5.07	 5.33	 5.94	 3.75	 4.56	 5.40	
Ampicillin	
	
5.50	 5.47	 5.60	 5.62	 6.28	 5.05	 4.48	 5.75	
Ampicillin	&		
CCCP	
5.46	 5.47	 5.51	 5.66	 6.21	 5.30	 4.22	 5.46	
Ampicillin	&		
PAβN	
5.62	 5.60	 5.51	 5.57	 6.10	 5.31	 4.30	 5.46	
Ampicillin	&		
Capsaicin	
5.39	 5.45	 5.53	 5.58	 6.26	 5.32	 4.12	 5.63	
Rifampicin	
	
5.59	 5.37	 5.58	 5.56	 5.97	 5.06	 4.43	 5.74	
Rifampicin	&		
CCCP	
5.44	 5.36	 5.62	 5.54	 6.24	 5.44	 3.52	 5.83	
Rifampicin	&		
PAβN	
5.31	 4.33	 5.55	 5.55	 6.40	 5.34	 4.00	 5.56	
Rifampicin	&		
Capsaicin	
5.50	 5.13	 5.53	 5.48	 6.36	 5.37	 4.00	 5.69	
Chloramphenicol	
	
5.35	 5.45	 5.67	 5.55	 6.51	 5.14	 4.30	 5.81	
Chloramphenicol		&		
CCCP	
5.34	 5.45	 5.63	 5.46	 6.43	 5.46	 4.60	 5.91	
Chloramphenicol	&		
PAβN	
5.40	 5.42	 5.65	 5.59	 6.54	 5.47	 4.60	 5.85	
Chloramphenicol	&		
Capsaicin	
5.75	 5.31	 5.57	 5.54	 6.47	 5.43	 4.60	 5.58	
Nalidixic	Acid	
	
5.41	 5.48	 5.64	 5.63	 6.63	 4.73	 4.78	 5.93	
Nalidixic	Acid	&		
CCCP	
5.69	 5.27	 5.75	 5.44	 6.43	 5.38	 4.85	 5.75	
Nalidixic	Acid	&		
PAβN	
5.55	 5.18	 5.69	 5.55	 6.59	 5.35	 4.43	 5.63	
Nalidixic	Acid	&		
Capsaicin	
5.68	 5.53	 5.62	 5.53	 6.45	 5.19	 4.64	 5.96	
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Table	7	E.	coli	K12	Wild	type	cfu/coupon	and	standard	error	(n=3)	
Treatment		 cfu/	coupon	 Standard	error		
Control	 5.32	x	105	 1.4	x	104	
CCCP	 4.55	x	104	 5	x	102	
PAβN	 8.5	x	103	 2.5	x	103	
Capsaicin	 3.32	x	105	 2.55	x	104	
Ampicillin	 5.9	x	104	 5	x	103	
Ampicillin	and	CCCP	 1.5	x	103	 5	x	102	
Ampicillin	and	PAβN	 5	x	102	 5	x	102	
Ampicillin	and	Capsaicin	 5	x	102	 5	x	102	
Rifampicin	 7.85	x	104	 1.95	x	104	
Rifampicin	and	CCCP	 1.1	x	104	 1	x	103	
Rifampicin	and	PAβN	 5	x	102	 5	x	102	
Rifampicin	and	Capsaicin	 1.5	x	103	 5	x	102	
Chloramphenicol		 9.6	x	104	 2	x	103	
Chloramphenicol	and	CCCP	 5	x	102	 5	x	102	
Chloramphenicol	and	PAβN	 0	 0	
Chloramphenicol	and	Capsaicin	 5	x	102	 5	x	102	
Nalidixic	acid		 1.5	x	103	 1.5	x	103	
Nalidixic	acid	and	CCCP	 7	x	103	 2	x	103	
Nalidixic	acid	and	PAβN	 1.5	x	103	 5	x	102	
Nalidixic	acid	and	Capsaicin		 2.95	x	104	 5.5	x	103	
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Table	8	tolC	deletion	cfu/coupon	and	Standard	error	(n=3)	
Treatment		 cfu/	coupon	 Standard	error		
Control	 4.78	x	104	 6.98	x	102	
CCCP	 2.67	x	102	 3.33	
PAβN	 6.67	x	101	 6.67	
Capsaicin	 1.04	x	104	 7.97	x	101	
Ampicillin	 1.06	x	104	 1.97	x	102	
Ampicillin	and	CCCP	 3.33	x	101	 3.33	
Ampicillin	and	PAβN	 0	 0	
Ampicillin	and	Capsaicin	 0	 0	
Rifampicin	 7.33	x	102	 2.19	x	101	
Rifampicin	and	CCCP	 2	x	102	 1	x	101	
Rifampicin	and	PAβN	 6.67	x	101	 6.67	
Rifampicin	and	Capsaicin	 1	x	102	 5.77	
Chloramphenicol		 2.33	x	102	 3.33	
Chloramphenicol	and	CCCP	 0	 0	
Chloramphenicol	and	PAβN	 0	 0	
Chloramphenicol	and	Capsaicin	 0	 0	
Nalidixic	acid		 1.51	x	104	 3.53	x	102	
Nalidixic	acid	and	CCCP	 0	 0	
Nalidixic	acid	and	PAβN	 0	 0	
Nalidixic	acid	and	Capsaicin		 1	x	102	 5.77	
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Table	9	acrB	deletion	cfu/coupon	and	Standard	error	(n=3)	
Treatment		 cfu/	coupon	 Standard	error		
Control	 1.41	x	106	 3.67	x	104	
CCCP	 1.53	x	105	 2.33	x	104	
PAβN	 1.17	x	105	 3.76	x	104	
Capsaicin	 1.07	x	105	 2.19	x	104	
Ampicillin	 4.13	x	105	 4.18	x	104	
Ampicillin	and	CCCP	 4	x	104	 1	x	104	
Ampicillin	and	PAβN	 0	 0	
Ampicillin	and	Capsaicin	 4.33	x	104	 1.45	x	104	
Rifampicin	 7	x	104	 2	x	104	
Rifampicin	and	CCCP	 3.33	x	104	 2.03	x	104	
Rifampicin	and	PAβN	 0	 0	
Rifampicin	and	Capsaicin	 1.13	x	105	 8.82	x	103	
Chloramphenicol		 5.5	x	105	 1	x	104	
Chloramphenicol	and	CCCP	 6.67	x	103	 6.67	x	103	
Chloramphenicol	and	PAβN	 0	 0	
Chloramphenicol	and	Capsaicin	 3.33	x	103	 3.33	x	103	
Nalidixic	acid		 2.43	x	105	 3.53	x	104	
Nalidixic	acid	and	CCCP	 1	x	104	 5.77	x	103	
Nalidixic	acid	and	PAβN	 0	 0	
Nalidixic	acid	and	Capsaicin		 3.33	x	103	 3.33	x	103	
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Table	10	acrA	deletion	cfu/	coupon	and	Standard	error	(n=3)	
Treatment		 cfu/	coupon	 Standard	error		
Control	 3.21	x	106	 2.19	x	105	
CCCP	 4.27	x	105	 5.17	x	104	
PAβN	 3	x	105	 2.08	x	104	
Capsaicin	 1.59	x	106	 5.51	x	104	
Ampicillin	 4.83	x	105	 6.36	x	104	
Ampicillin	and	CCCP	 2	x	105	 2.08	x	104	
Ampicillin	and	PAβN	 3.33	x	104	 3.33	x	103	
Ampicillin	and	Capsaicin	 1.23	x	105	 8.82	x	103	
Rifampicin	 8.7	x	105	 2.62	x	105	
Rifampicin	and	CCCP	 4.2	x	105	 1.53	x	104	
Rifampicin	and	PAβN	 1.53	x	105	 1.33	x	104	
Rifampicin	and	Capsaicin	 8.13	x	105	 1.33	x	104	
Chloramphenicol		 5.33	x	105	 8.11	x	104	
Chloramphenicol	and	CCCP	 1.67	x	105	 5.36	x	104	
Chloramphenicol	and	PAβN	 0	 0	
Chloramphenicol	and	Capsaicin	 3.33	x	104	 3.33	x	103	
Nalidixic	acid		 1.09	x	106	 9.06	x	104	
Nalidixic	acid	and	CCCP	 1.67	x	105	 2.03	x	104	
Nalidixic	acid	and	PAβN	 3.33	x	103	 3.33	x	103	
Nalidixic	acid	and	Capsaicin		 3.67	x	104	 8.82	x	103	
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Table	11	emrA	deletion	mutant	cfu/	coupon	and	Standard	error	(n=3)	
Treatment		 cfu/	coupon	 Standard	error		
Control	 4.48	x	107	 4.71	x	105	
CCCP	 8.47	x	106	 3.38	x	104	
PAβN	 7	x	105	 5.77	x	103	
Capsaicin	 3.3	x	106	 4.58	x	104	
Ampicillin	 1.93	x	106	 1.2	x	104	
Ampicillin	and	CCCP	 8	x	105	 1.53	x	104	
Ampicillin	and	PAβN	 0	 0	
Ampicillin	and	Capsaicin	 1.53	x	106	 2.19	x	104	
Rifampicin	 1.93	x	106	 2.08	x	104	
Rifampicin	and	CCCP	 1.1	x	106	 2.08	x	104	
Rifampicin	and	PAβN	 5	x	105	 5.77	x	103	
Rifampicin	and	Capsaicin	 1.3	x	106	 5.77	x	103	
Chloramphenicol		 2.27	x	106	 4.33	x	104	
Chloramphenicol	and	CCCP	 1	x	105	 0	
Chloramphenicol	and	PAβN	 0	 0	
Chloramphenicol	and	Capsaicin	 4.00	x	105	 5.77	x	103	
Nalidixic	acid		 7.37	x	106	 9.24	x	104	
Nalidixic	acid	and	CCCP	 4.00	x	104	 1x	104	
Nalidixic	acid	and	PAβN	 0	 0	
Nalidixic	acid	and	Capsaicin		 4.33	x	105	 6.67	x	103	
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